<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Jimeng on Medium]]></title>
        <description><![CDATA[Stories by Jimeng on Medium]]></description>
        <link>https://medium.com/@jimeng_57761?source=rss-5c0308f333cc------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*ZOTekHzSIeuubFPFGpP4YA.png</url>
            <title>Stories by Jimeng on Medium</title>
            <link>https://medium.com/@jimeng_57761?source=rss-5c0308f333cc------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Mon, 16 Nov 2026 17:42:18 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@jimeng_57761/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[One Shot at Approval: How the FDA’s Single-Trial Shift Changes Clinical Development]]></title>
            <link>https://medium.com/keiji-ai/one-shot-at-approval-how-the-fdas-single-trial-shift-changes-clinical-development-aba0f184eeea?source=rss-5c0308f333cc------2</link>
            <guid isPermaLink="false">https://medium.com/p/aba0f184eeea</guid>
            <category><![CDATA[ai]]></category>
            <dc:creator><![CDATA[Jimeng]]></dc:creator>
            <pubDate>Tue, 17 Mar 2026 04:23:00 GMT</pubDate>
            <atom:updated>2026-03-17T04:23:57.060Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*Z5uQULAalNfM2AuI" /><figcaption>FDA is replacing two-trial approval policy with one-trial approval</figcaption></figure><p>The FDA made it official in February 2026: one well-controlled pivotal trial, paired with confirmatory evidence, is now the default pathway for new drug approvals. Commissioner Makary and CBER Director Prasad didn’t mince words — the two-trial standard was outdated. The data backed them up. Roughly two-thirds of novel drugs approved in 2024 were already cleared on a single trial.</p><p>For sponsors, this is both an opportunity and a pressure test.</p><p>The upside is real: fewer trials mean shorter timelines, lower costs, and faster paths to patients. But the math also works the other way. When you have one shot, every design decision carries more weight. A flawed endpoint selection, an underpowered sample, a protocol that doesn’t survive an adaptive interim — these aren’t recoverable errors anymore. There’s no second trial to correct course.</p><p>This is the environment where AI-powered trial design stops being a competitive advantage and starts being a necessity.</p><h3><strong>What “One Shot” Actually Demands</strong></h3><p>A successful single pivotal trial requires sponsors to front-load the analytical rigor that used to be spread across multiple programs. That means:</p><p>- Choosing the right primary endpoint with evidence to support its regulatory defensibility<br>- Designing a protocol robust enough to handle adaptive modifications without compromising statistical integrity<br>- Synthesizing the existing literature and real-world evidence that will serve as the “confirmatory” layer FDA now expects alongside the pivotal data<br>- Modeling trial outcomes before first patient in — not after</p><p>Each of these is a domain-specific problem. Generic AI tools aren’t built for them. TrialMind is.</p><h3>Where TrialMind’s Agents Apply Directly</h3><p>TrialMind’s Trial Design Optimization and Digital Twin Simulation agents address the core challenge: protocol design under uncertainty. The digital twin framework lets sponsors simulate thousands of trial scenarios — varying enrollment rates, dropout assumptions, interim analysis rules — before committing to a design. When you’re designing your one pivotal study, that simulation layer isn’t optional.</p><p>The Systematic Literature Review Automation agent (PRISMA-compliant) handles the confirmatory evidence problem. FDA isn’t asking sponsors to run a second trial — they’re asking for rigorous synthesis of existing evidence. Automated, auditable literature review that maps to regulatory standards is how you build that dossier without adding months to your timeline.</p><p>The Biostatistics Programming agent handles SDTM/ADaM-compliant analysis datasets and TFL generation. In a single-trial world, the statistical analysis plan has to be bulletproof from day one. Any ambiguity in the programming layer becomes a review question from FDA. Automation with built-in CDISC standards compliance removes that surface area for error.</p><p>Finally, the Regulatory Writing agents — covering CSR and protocol writing — matter more in a compressed pathway. When the program is built on one trial, the quality of the regulatory package defines the outcome. Clear, complete, traceable documentation isn’t a cleanup task at the end; it’s woven into how the trial is designed.</p><h3><strong>The Numbers Behind the Confidence</strong></h3><p>TrialMind’s underlying research isn’t hypothetical. The DeepEvidence benchmark (<a href="https://arxiv.org/abs/2601.11560">arXiv 2025</a>) shows 12x performance improvement on Humanity’s Last Exam HLE-Medicine versus comparable models, with 1.7x advantage on LabBench-LitQA2 and 1.6x on MOA and pathway reasoning. These aren’t vanity metrics — they reflect what happens when AI is trained specifically on clinical research data rather than adapted from general-purpose foundations.</p><p>The platform draws on 1M+ trial data points and is deployed at production scale at AbbVie, Regeneron, Takeda, and Guardant Health, among others. The team behind it — including former Global Head of AI Research at IQVIA — has published 100+ papers in Nature, NeurIPS, and peer-reviewed clinical journals. The science backing TrialMind is the same science that informs the agents sponsors are using to design their programs.</p><h3>A New Standard for Pivotal Trial Design</h3><p>FDA’s single-trial default doesn’t reduce the evidentiary bar for approval. It concentrates it. Sponsors who succeed in this environment will be those who apply more analytical sophistication earlier in development — not less.</p><p>The companies that deploy AI across the full trial lifecycle, from protocol design through statistical programming to regulatory writing, will have a structural advantage. Not because AI is novel, but because getting a single pivotal trial right requires more simultaneous analytical precision than any human team can sustain at the required speed.</p><p>The FDA changed the rules. The question for every sponsor is whether their development infrastructure is built for one chance — or still designed for two.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=aba0f184eeea" width="1" height="1" alt=""><hr><p><a href="https://medium.com/keiji-ai/one-shot-at-approval-how-the-fdas-single-trial-shift-changes-clinical-development-aba0f184eeea">One Shot at Approval: How the FDA’s Single-Trial Shift Changes Clinical Development</a> was originally published in <a href="https://medium.com/keiji-ai">Keiji AI</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[When Cursor silently raised their price by over 20× and more, what is the message the users are…]]></title>
            <link>https://medium.com/@jimeng_57761/when-cursor-silently-raised-their-price-by-over-20-and-more-what-is-the-message-the-users-are-6af93385f362?source=rss-5c0308f333cc------2</link>
            <guid isPermaLink="false">https://medium.com/p/6af93385f362</guid>
            <dc:creator><![CDATA[Jimeng]]></dc:creator>
            <pubDate>Tue, 17 Feb 2026 08:08:34 GMT</pubDate>
            <atom:updated>2026-02-17T08:08:34.635Z</atom:updated>
            <content:encoded><![CDATA[<h3>When Cursor silently raised their price by over 20× and more, what is the message the users are getting</h3><p>Cursor’s pricing controversy is best understood as a shift from <strong>request-based SaaS packaging</strong> (“500 fast premium requests + unlimited slow requests”) to <strong>metered compute</strong> (credits priced at underlying LLM API rates, where marginal cost varies dramatically with context size, tool calls, and model choice). The result: even if the headline subscription price stayed around <strong>$20/month</strong>, the <em>effective</em> price for many workflows — especially agentic, long-context coding — can plausibly jump <strong>20× or more</strong>.</p><p>A composite anecdote that matches <a href="https://techcrunch.com/2025/07/07/cursor-apologizes-for-unclear-pricing-changes-that-upset-users/">what many teams reported during the rollout</a>. Our own small team of 5 spent over $4600 in just 6 weeks in 2026, about double of our entire 2025 spending.</p><h3><strong>What happened.</strong></h3><p>Now let’s look closely about how 20x pricing increases is actually possible:</p><ul><li><strong>Actual overage stories</strong>: a Hacker News commenter reported “$350 on Cursor overage in like a week” (≈$1,400/month), a ~70× monthly equivalent vs the legacy “$20-ish” mental model.</li><li><strong>Marginal cost inflation</strong>: earlier, Cursor staff described usage-based premium requests as a flat <strong>$0.04/request</strong>; after June 2025, Cursor tied usage to direct API-equivalent rates, meaning large-context/agent loops can plausibly jump from pennies to dollars per “interaction.”</li></ul><p>The message users <em>hear</em> is less “we raised prices” and more: <strong>“</strong><a href="https://cursor.com/blog/june-2025-pricing"><strong>your workflow is now a metered compute budget; ‘unlimited’ is conditional; and you need cost governance like you would for cloud infra.</strong></a><strong>”</strong></p><h3>Timeline of Cursor pricing changes</h3><p>The cleanest before/after anchor is an archived pricing page:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*g3zb2nt48ADRVDea3IRpbQ.png" /></figure><ul><li><strong>Dec 31, 2024 (Wayback snapshot)</strong>: Pro is $20/month with “500 fast premium requests per month” and “Unlimited slow premium requests.” The page also links a “Changelog,” suggesting pricing and product updates are meant to be trackable — even if pricing shifts later felt “silent” to users.</li><li><strong>Sep 2024 (forum)</strong>: buying an extra 500 fast requests was described as +$20/month (i.e., $40 total), reinforcing the simple “requests as currency” model.</li><li><strong>Jan 2025 (forum staff)</strong>: Cursor staff described usage-based premium requests at <strong>$0.04/request</strong> (“500 requests … same $20 price”).</li><li><strong>Jun–Jul 2025 (official blog + community)</strong>: Cursor moved from request-based pricing to <strong>“$20 of included usage on Pro”</strong> and advertised “unlimited usage” when <strong>Auto</strong> is selected. The company later apologized for unclear communication.</li><li><strong>Jul 2025 (official forum megathread)</strong>: Cursor staff summarized the new system: credits are consumed “at the same rate you would via the LLMs’ direct APIs.”</li><li><strong>2026 pricing page</strong>: tiers emphasize multipliers — Pro ($20), Pro+ ($60, “3× usage”), Ultra ($200, “20× usage”), and Teams ($40/user) with org controls and usage reporting.</li></ul><h4>The “unit price” story: $0.04/request → “it depends” (and can hit dollars)</h4><p>In early 2025, Cursor staff explicitly anchored usage-based premium requests at <strong>$0.04/request</strong>.</p><p>After the shift, Cursor said the hardest requests can cost <strong>~10×</strong> simple ones because newer models can burn more tokens on longer-horizon tasks. And Cursor staff said credits burn at the same rate as direct APIs.</p><p>Token math makes “20×+ per interaction” plausible. For example, Claude Sonnet 4.5 is priced at <strong>$3 / 1M input tokens</strong> and <strong>$15 / 1M output tokens</strong>. <br>If a single agentic prompt effectively sends 350k input tokens (repo context + tool outputs) and emits 20k output tokens (multi-file diffs), that’s roughly:</p><ul><li>Input cost: 0.35M × $3 ≈ $1.05</li><li>Output cost: 0.02M × $15 ≈ $0.30</li><li>Total ≈ <strong>$1.35</strong></li></ul><p>Compared to $0.04/request, that’s ~34× for a “one request” mental model — <em>without</em> needing any exotic assumptions beyond “big context + agent work.”</p><h3>The “real bills” story: spend patterns (not list price) explode</h3><p>User reactions repeatedly frame the change as surprise overages:</p><ul><li>Hacker News: “<a href="https://news.ycombinator.com/item?id=44185256">I spent $350 on Cursor overage in like a week.</a>”</li><li>Reddit /r/programming: “<a href="https://www.reddit.com/r/programming/comments/1lu8eyb/cursor_pay_more_get_less_and_dont_ask_how_it_works/">silent nerfs and quiet upsells… zero clarity,” reflecting the perception of “silent” price pressure</a>.</li><li>TechCrunch:<a href="https://techcrunch.com/2025/07/07/cursor-apologizes-for-unclear-pricing-changes-that-upset-users/"> Cursor’s CEO apologized after unclear pricing changes led some users to be charged more; after the $20 limit, users had to buy more credits to continue with selected models.</a></li><li><a href="https://x.com/therealdanvega/status/1896556599206162848">X posts reflect the same “credits → forced upgrade” narrative (e.g., needing to move to $60/month).</a></li></ul><h3>What is the backlash?</h3><p>Across Reddit, Hacker News, and X, the consistent themes aren’t “LLMs should be free,” but:</p><ul><li><strong>“Unlimited” is now conditional</strong>: users interpret “unlimited” as “only if Auto chooses for you,” which feels like giving up control over quality and predictability.</li><li><strong>Cost has shifted from predictable subscription to “cloud billing psychology.”</strong> People describe credit counters as anxiety-inducing and opaque.</li><li><strong>The company expects teams to manage spend like infra</strong>: budgets, thresholds, usage analytics — features now emphasized on Teams/Enterprise tiers.</li><li><strong>But the product is still valued</strong>: G2 reviews praise productivity and context-aware suggestions, while also calling the subscription “a tad bit expensive.”</li></ul><p>In other words, users hear: <strong>“We’re no longer subsidizing heavy workflows; pay for compute or accept Auto; and if you’re a ‘whale,’ you’ll be segmented into higher tiers.”</strong></p><h3>What can you do?</h3><h4>External APIs vs self-hosted/local models</h4><h4>Cost: per-token is cheap… until you scale or go agentic</h4><p>Token prices (representative examples):</p><ul><li>OpenAI gpt-4.1: <strong>$2 / 1M input</strong>, <strong>$8 / 1M output</strong>.</li><li>Claude Sonnet 4.5: <strong>$3 / 1M input</strong>, <strong>$15 / 1M output</strong>.</li><li>Gemini 3 Flash: <strong>$0.50 / 1M input</strong>, <strong>$3 / 1M output</strong>.</li></ul><p><strong>Pricing scenarios (80% input / 20% output; illustrative):</strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*4nFrrM7y3uJy_5LkP5zCFg.png" /></figure><p><strong>Self-hosting</strong> flips you to fixed(ish) infra cost + ops. Google Cloud’s GPU pricing illustrates per-hour GPU billing (e.g., $0.55/hr for an NVIDIA T4 Virtual Workstation SKU). Even ignoring CPU/storage, a single always-on GPU is hundreds of dollars/month; the break-even comes only at very high token volumes or when you strongly value data locality.The rest of the decision (latency, governance, lock-in)</p><h4>The rest of the decision (latency, governance, lock-in)</h4><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*30rcaBmk4TY06cpncCsTEA.png" /></figure><h4>Cursor for programming and alternatives</h4><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*o93AnX_cRsh-bFOlBhk5kw.png" /></figure><p><strong>Security note for all agentic tools:</strong> Once AI can execute code, modify files, or call APIs, prompt injection becomes a real attack vector. Review permissions carefully, sandbox where possible, and audit agent actions in production environments.</p><h4>Recommended migration strategies and team decision framework</h4><h4>Migration playbook</h4><ul><li><strong>Instrument first, migrate second</strong>: measure tokens per dev/day and which workflows blow up (agents, long-context refactors). Cursor itself recommends clarity via its updated pricing explanations.</li><li><strong>Adopt a “cheap-default, expensive-on-purpose” model policy</strong>: default to Auto/cheaper models for routine edits; reserve frontier models for code review, architecture, and tricky bugs.</li><li><strong>Split workflows</strong>: keep Cursor-like IDE help for in-editor speed, but route heavyweight repo-wide reasoning to a centralized API gateway where you can enforce budgets, caching, and logging.</li><li><strong>For sensitive code</strong>: evaluate private deployment or self-hosted open models, but treat it as an infrastructure project.</li></ul><h3><strong>What are the core issues</strong></h3><h4><strong>The Core Tension: Predictability vs. Compute Reality</strong></h4><p>In vertical AI companies that combine subscription and usage-based pricing, the central strategic tension lies between predictability and compute reality. Customers expect SaaS simplicity: a clear monthly fee, stable budgeting, and no surprises. Yet AI infrastructure runs on metered economics — tokens, GPU time, model calls — and costs can fluctuate significantly depending on workload intensity.</p><p>When a product presents a clean subscription model but underlying usage can multiply actual costs several times over, a psychological contract is strained. Even if pricing mechanics are technically sound, users anchor to the subscription number. If a $20 plan routinely leads to $400 or $800 bills for active teams, the perception becomes one of escalation rather than value alignment. The larger the gap between the subscription anchor and actual spend, the faster trust erodes.</p><h4><strong>Expectation Mismatch and Trust Erosion</strong></h4><p>Large deltas between subscription and usage create structural problems. Anchoring bias establishes a mental model that is difficult to reset. Once users internalize a baseline subscription price, substantial variance feels like a breach of implied value. Even without intent, <strong>the perception of bait-and-switch</strong> can emerge.</p><p>In B2B contexts, the issue compounds. Finance teams prioritize predictability and procurement clarity. Variable AI-driven billing that resembles cloud infrastructure invoices introduces friction. If pricing resembles metered compute rather than SaaS, buyers evaluate it as infrastructure — subject to different scrutiny, approval cycles, and negotiation dynamics. The product’s perceived category subtly shifts.</p><h4><strong>What a Healthy Subscription + Usage Model Looks Like</strong></h4><p>A sustainable pricing structure ensures that subscription covers core product value, while usage pricing provides bounded elasticity. The subscription should clearly encompass workflow access, user interface, integrations, governance, compliance, collaboration features, and support. Usage charges should scale when customers extract proportionally more business value — not when internal token consumption fluctuates unpredictably.</p><p>When usage feels like value expansion rather than infrastructure volatility, customers perceive fairness. The relationship between product value and billing becomes intuitive rather than adversarial.</p><h4><strong>Bounded Multipliers and Clear Segmentation</strong></h4><p>Usage multipliers must remain bounded. If a Pro plan is priced at $50 per month, typical heavy users should not regularly experience 10–20× effective cost scaling. Power users may justify moderate expansion, but extreme variance signals pricing misalignment.</p><p>The strategic solution is segmentation, not surprise. Clear higher-tier plans for advanced workflows protect both margin and trust. Heavy users should know upfront which tier matches their workload, rather than discovering it retroactively through billing overages. Transparent segmentation strengthens long-term relationships.</p><h4><strong>Align Billing With User Mental Models</strong></h4><p>Billing units shape perception. Charging in tokens or GPU seconds exposes infrastructure abstraction and disconnects pricing from user outcomes. Vertical AI products should bill in domain-native units: documents analyzed, protocols generated, repositories indexed, cases processed, reports delivered. When billing aligns with tangible domain value, pricing reinforces product positioning. When it aligns with backend compute mechanics, it exposes volatility and weakens value clarity.</p><h4><strong>Value-Based Pricing vs. Compute-Based Pricing</strong></h4><p>Pricing tightly coupled to upstream API costs inherits vendor volatility. If token prices shift or model behavior changes, customer pricing must shift as well, undermining predictability. Durable vertical AI businesses absorb reasonable compute variance within tier structures and optimize internally through routing, caching, and model selection.</p><p>Revenue should scale with workflow impact and integration depth, not merely with token burn. Over-coupling revenue growth to compute consumption shifts the company’s identity from product company to compute reseller, weakening long-term defensibility.</p><h4><strong>Architecture and Pricing Stability</strong></h4><p>Infrastructure decisions influence pricing resilience. Companies relying exclusively on external APIs benefit from speed and frontier model access but inherit cost variability and margin uncertainty. Hosting local or open-weight models provides predictable infrastructure cost and margin control but introduces operational complexity and MLOps burden. A hybrid approach often offers the best balance. Frontier APIs can support high-value, high-precision workflows, while cheaper or locally hosted models handle routine tasks. A routing layer smooths cost variance and protects subscription integrity. Pricing stability ultimately depends on architectural discipline.</p><h4><strong>The Long-Term Moat in Vertical AI</strong></h4><p>Durable differentiation in vertical AI arises from workflow depth, proprietary datasets, domain fine-tuning, compliance infrastructure, integration into enterprise processes, and switching costs. It does not arise from token resale margins. A practical heuristic is that subscription revenue should constitute the majority of predictable income, with usage serving as a bounded elasticity buffer. When usage dominates revenue, the company behaves like infrastructure. When subscription absorbs most variance and usage scales moderately with value expansion, the company behaves like a product company.</p><h4><strong>Final Reflection: Pricing as Strategic Signal</strong></h4><p>Large gaps between subscription and usage pricing send an unintended signal: that growth optimization has taken precedence over predictability. In vertical AI, trust compounds slowly while billing surprises compound quickly.</p><p>Pricing architecture is not merely a financial lever; it is a strategic declaration of how a company intends to grow alongside its customers. Stable, aligned pricing communicates confidence. Volatile, surprise-driven pricing communicates fragility. Over time, customers respond accordingly.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=6af93385f362" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Don’t Delegate, Do It Yourself — The New Way to Work in the Age of AI]]></title>
            <link>https://medium.com/keiji-ai/dont-delegate-do-it-yourself-the-new-way-to-work-in-the-age-of-ai-a1c9a81b40cc?source=rss-5c0308f333cc------2</link>
            <guid isPermaLink="false">https://medium.com/p/a1c9a81b40cc</guid>
            <category><![CDATA[ai]]></category>
            <category><![CDATA[leadership]]></category>
            <dc:creator><![CDATA[Jimeng]]></dc:creator>
            <pubDate>Thu, 29 Jan 2026 22:54:34 GMT</pubDate>
            <atom:updated>2026-05-06T03:04:24.319Z</atom:updated>
            <content:encoded><![CDATA[<h3>Don’t Delegate, Do It Yourself — The New Way to Work in the Age of AI</h3><p>For fifty years, the best career advice was simple: learn to delegate. As you rise, stop doing and start managing. Your job is to set direction, hire well, and get out of the way. <br> <br> <strong>That advice is now wrong.</strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*KYcaMqbPudgzJLPTVe-cDA.png" /><figcaption>The leader who do</figcaption></figure><h3>The Gospel of Delegation</h3><p>We inherited our management philosophy from the industrial era. Peter Drucker taught us that a manager’s job is to multiply output through others. The assembly line proved it: one person can only do so much, but one person directing ten can do ten times more. <br> <br>This logic carried into the knowledge economy. Senior leaders were supposed to operate at higher levels of abstraction. You don’t write the <br> memo — you review it. You don’t build the model — you interpret it. You don’t code the feature — you prioritize it. <br> <br>Delegation became a status symbol. The more senior you were, the less you did yourself. “I have people for that” was a flex.</p><p>The math made sense. If explaining a task took 30 minutes and doing it took 3 hours, delegation was obvious. You bought back 2.5 hours to spend on “higher-leverage” work, which usually meant more meetings about work others would do.</p><h3>What Changed</h3><p>AI broke the equation. The same task that took your team three days now takes you 10 minutes — because<strong> you have the context, the taste, and now, the tools. </strong><br>Consider what’s changed: <br> — Writing: A document that took a week of drafts and reviews now takes an afternoon with AI assistance. <br> — Analysis: Data work that required a data scientist, a week, and three Slack threads now happens in a conversation. <br> — Research: Competitive analysis, market sizing, literature review — hours instead of weeks. <br> — Code: Functional prototypes that required an engineering sprint now emerge in a day. <br>— Sales: Prospect research, outreach emails, proposal drafts, CRM updates: what took a sales ops team now takes minutes. <br>— Marketing: Blog posts, social content, competitive positioning, conference research: a founder can now do what required an agency.</p><p>The bottleneck has shifted. Explaining what you want — transferring context to another person — now takes longer than just doing it.<strong> Every delegation involves a lossy compression</strong>: your full understanding reduced to a brief, a ticket, a meeting. The recipient fills gaps with assumptions. You review, correct, iterate. Weeks pass. Or you could have done it yourself in an hour.</p><h3>Leaders Who Build</h3><p>The best leaders have noticed. They’re becoming individual contributors again — not because they have to, but because it’s now the highest-leverage use of their time. <br>- Jensen Huang runs NVIDIA with 60 direct reports and no scheduled 1:1s. He stays focused on chip architecture, strategy, and product. No layers of abstraction. No delegation chains. Just a CEO who still does the work. <br>- Brian Chesky flattened Airbnb in 2020, eliminating most middle management. He got closer to the product, reviewing designs personally, making decisions that would have been delegated three levels down. Airbnb’s stock has tripled since. <br>- Tobi Lütke told Shopify employees: before asking for more headcount, show me how you’ve used AI. He expects everyone — including himself — to use AI as a first resort, not after exhausting human options. <br>- Patrick Collison still reviews code at Stripe, a company worth $95 billion. He writes internal documents. He stays technical. He could delegate everything. He chooses not to.</p><p>These aren’t micromanagers. They’re leaders who realized that with AI, their personal output can be extraordinary — and that delegating actually slows things down.<br> <br><strong>My Own Setup </strong><br> I run an AI company. I could delegate everything. Instead, I’ve built a personal operating system that lets me do the work of an entire support staff — instantly. <br> <br>My core setup is Cursor + Claude Code, an AI-powered development environment that connects to everything I need through the Model Context Protocol (MCP). With Zapier MCP integrations, I’ve wired Claude directly into my productivity stack: <br> — Google Calendar — I paste a conference invitation into Claude, and the event is on my calendar in seconds, with all the details parsed and <br> reminders set. <br> — Gmail — I draft and send emails by describing what I want. Sponsorship inquiries, investor updates, customer follow-ups — done without <br> opening Gmail. <br> — Google Drive — File organization, document retrieval, content management — all through conversation. <br> — Jira — Bug reports and feature requests go from my head to tickets in seconds. I describe the issue; Claude creates the ticket with proper <br> formatting, acceptance criteria, and the right project. <br> — Overleaf — I still write academic papers. Claude helps me draft sections, manage LaTeX, and iterate on manuscripts without switching <br> contexts. <br> <br> And for my company’s domain — clinical trials and biomedical research — I use our own <strong>TrialMind agents</strong>. Literature review, protocol analysis, <br> real-world evidence queries. The same AI tools we sell to pharma companies, I use daily to stay close to the science. <br> <br>The result: tasks that would have required an EA, a chief of staff, and half my ops team now happen in the flow of my thinking. I don’t schedule time to “process email” or “update Jira.” I just do it, in seconds, whenever the thought occurs. This isn’t about working more hours. It’s about removing the friction between intention and execution. When doing something takes the same effort as asking someone else to do it, you just do it.</p><p>A friend recently joked that the new trend isn’t scrolling TikTok — it’s chatting with Claude Code. I laughed, then realized I wasn’t sure if she was joking.</p><h3><strong>The Case for Doing It Yourself</strong></h3><p><strong>Speed</strong>. No scheduling, no briefs, no waiting. You think, you execute, you ship. The feedback loop is minutes, not weeks. <br><strong>Quality</strong>. Your standards, uncompromised. No game of telephone where your vision gets diluted through layers of interpretation. The output <br> matches what’s in your head. <br> <strong>Learning</strong>. You stay sharp. Leaders who delegate everything eventually lose the ability to do anything. They become dependent on their teams for<br> judgment. They can’t tell good work from bad because they’ve forgotten what the work feels like. <br><strong>Satisfaction</strong>. There’s a reason craftspeople are happier than coordinators. Making things is deeply satisfying. Managing the making of things <br> is not.</p><h3>The Honest Cons</h3><p>This isn’t a free lunch. <br> <strong>Team development</strong> suffers. If you do everything, your team doesn’t grow. Delegation was training. Without it, you might ship faster, but build <br> weaker organizations.<br> <strong>Burnout</strong> is real. AI expands what’s possible, but your calendar doesn’t expand. Doing more yourself means saying no to other things — or <br> burning out. <br> <strong>Some work </strong>still needs humans. Relationships, negotiation, presence, judgment in ambiguous situations — AI can’t replace these. Not everything <br> should be done yourself, even if it could be. <br> <strong>Identity is hard</strong>. Many leaders built careers on their ability to manage, delegate, and orchestrate. If that’s no longer valuable, who are <br> they? This shift will be psychologically difficult for many people.</p><h3>The New Leader</h3><p>The future leader is a player-coach — but not the compromised version we used to imagine, splitting time awkwardly between doing and managing.<br> The new player-coach does the important work directly and coaches AI to handle the rest.</p><p>The org chart implications are significant: <br> — Fewer layers. If leaders can execute, you need fewer people to execute for them.<br> — Smaller teams. A person with AI can do what a team of five did before.<br> — New definition of senior. Seniority should mean “ships more impact,” not “manages more people.” <br> <br> The skills that matter are changing too. <strong>Taste matters more than ever </strong>— AI can generate infinite options, but someone has to choose. Tool fluency is a real skill — knowing how to wire AI into your workflow, not just chat with it occasionally. And the old fundamentals still apply: <strong>clear thinking, good judgment, deep expertise.</strong></p><h3>What To Do</h3><p>If you’re a leader who’s been delegating by default, try an experiment. Pick one task you’ve been handing off. Something that requires context you have, and your team doesn’t. A strategy document. A competitive <br> analysis. A product decision.</p><p>Do it yourself. With AI. (Not just ChatGPT, research what AI tools can help you the most on this task, and try several of them, compare and learn.) <br> See how long it takes. See how good it is. See how it feels. <br> <br> My guess: you’ll do it faster, better, and enjoy it more than you expected. And you’ll start questioning what else you’ve been delegating out of habit rather than logic. <br> <br>The age of AI doesn’t make leaders less necessary. It makes <em>leaders who do</em> more valuable than <em>leaders who delegate</em>. Stop managing. Start making.</p><p><em>*Jimeng Sun is the CEO of Keiji AI, building TrialMind — AI agents for clinical research. He is also a professor at University of Illinois Urbana-Champaign now and previously at Georgia Tech working on AI and healthcare.*</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=a1c9a81b40cc" width="1" height="1" alt=""><hr><p><a href="https://medium.com/keiji-ai/dont-delegate-do-it-yourself-the-new-way-to-work-in-the-age-of-ai-a1c9a81b40cc">Don’t Delegate, Do It Yourself — The New Way to Work in the Age of AI</a> was originally published in <a href="https://medium.com/keiji-ai">Keiji AI</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The AI Regulation Revolution: How New FDA and EMA Guidance Opens the Clinical Trials Market]]></title>
            <link>https://medium.com/keiji-ai/the-ai-regulation-revolution-how-new-fda-and-ema-guidance-opens-the-clinical-trials-market-6049d1d53c11?source=rss-5c0308f333cc------2</link>
            <guid isPermaLink="false">https://medium.com/p/6049d1d53c11</guid>
            <dc:creator><![CDATA[Jimeng]]></dc:creator>
            <pubDate>Thu, 15 Jan 2026 12:27:12 GMT</pubDate>
            <atom:updated>2026-01-15T12:29:07.096Z</atom:updated>
            <content:encoded><![CDATA[<p>Jimeng Sun and TrialMind</p><p>A comprehensive guide to the regulatory frameworks reshaping AI innovation in drug development</p><h3>The Watershed Moment</h3><p>January 2025 marked a turning point for artificial intelligence in clinical trials. Within months of each other, the FDA released its draft guidance on “Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products,” and the EMA published its reflection paper on AI across the medicinal product lifecycle. Together, these documents don’t just regulate AI — they <strong>legitimize it</strong> as a core technology in drug development.</p><p>For AI companies operating in the clinical trials space, this is the moment you’ve been waiting for. The regulatory fog has lifted, revealing a clear pathway forward. But success will belong to those who understand not just the requirements, but the <strong>strategic opportunities</strong> these frameworks create.</p><h3>What These Policies Actually Say</h3><h3>The FDA’s Risk-Based Framework</h3><p>The FDA introduces a structured, five-step “credibility assessment” process that treats AI like any other scientific tool — requiring validation proportional to its regulatory impact:</p><p>1. <strong>Define your question</strong> — What decision is the AI supporting?</p><p>2. <strong>Define Context of Use (COU)</strong> — How specifically will the AI be deployed?</p><p>3. <strong>Assess model influence</strong> — Is the AI’s output directly used or merely corroborative?</p><p>4. <strong>Identify credibility gaps</strong> — Where might the model fail or mislead?</p><p>5. <strong>Implement risk-based oversight</strong> — Match validation rigor to patient impact</p><p>This isn’t a checkbox exercise. The FDA makes clear that <strong>high-influence AI</strong> (directly determining endpoints, patient selection, or dosing) requires the same evidentiary standards as any clinical measurement tool. Lower-influence applications (supporting exploratory analyses, generating hypotheses) face proportionally lighter requirements.</p><p><strong>The critical insight</strong>: The FDA isn’t asking “should we allow AI?” They’re asking “how do we validate it appropriately?”</p><h3>The EMA’s Lifecycle Perspective</h3><p>The European regulator takes a broader view, addressing AI across the entire medicinal product lifecycle — from drug discovery through post-market surveillance. Key positions include:</p><p>· <strong>AI in pivotal trials requires model freezing before database lock</strong> — No incremental learning, no post-hoc optimization</p><p>· <strong>Prospective validation is mandatory</strong> — Retrospective performance isn’t enough</p><p>· <strong>Transparency scales with risk</strong> — Explainability requirements intensify as patient impact increases</p><p>· <strong>Open science is encouraged</strong> — Publishing validated models in repositories builds standardization</p><p>· <strong>Precision medicine gets explicit support</strong> — AI for biomarker-driven treatment selection is welcomed</p><p>The EMA signals that <strong>AI is mature enough for confirmatory evidence</strong> — a massive validation for the field.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/515/1*fzBT5Gz3hxJ9wfus-L6P_A.png" /></figure><p><strong>Figure 2.1.</strong> FDA’s 5-Step Credibility Assessment Framework showing risk-based validation pathways for AI models</p><h3>The Three Big Impacts on AI Companies</h3><h3>Impact #1: “Regulatory-Ready” Becomes Table Stakes</h3><p>Gone are the days when AI companies could build first and figure out compliance later. These policies make clear that <strong>regulatory preparedness is product infrastructure</strong>, not a documentation afterthought.</p><p>What this means in practice: — <strong>Model versioning must be cryptographically verifiable</strong> — Auditors will demand proof that your production model matches your validation studies — <strong>Every data transformation must be traceable</strong> — The provenance chain from raw data to model output needs full lineage — <strong>Explainability must be built-in, not bolted-on</strong> — You can’t add interpretability to a black box after deployment</p><p><strong>Winners</strong>: AI platforms architected from day one around audit trails, version control, and transparency</p><p><strong>Losers</strong>: Companies treating regulatory documentation as a post-processing step</p><h3>Impact #2: The Bar for Pivotal Trials Is High — But Clear</h3><p>Both regulators send an unmistakable message: AI can support pivotal, confirmatory evidence for regulatory approval. But the requirements are stringent:</p><p>· Models must be <strong>locked before unblinding</strong> (EMA explicitly forbids adaptive learning in Phase 3)</p><p>· Performance must be demonstrated on <strong>prospective data</strong> from the target population</p><p>· All model decisions must be <strong>pre-specified in the Statistical Analysis Plan</strong></p><p>· Bias assessment across demographic subgroups is <strong>mandatory, not optional</strong></p><p>This is simultaneously a constraint and an opportunity. The constraint: you can’t iterate your way to success during a pivotal trial. The opportunity: <strong>sponsors now have confidence that AI-derived endpoints will be accepted</strong> if properly validated.</p><h3>Impact #3: Engagement Is Encouraged — Even Expected</h3><p>Perhaps most surprisingly, both documents actively invite pre-submission dialogue. The FDA lists <strong>four separate pathways</strong> for early engagement on AI (Type C meetings, CATT program, MIDD paired meetings, RWE program). The EMA explicitly encourages protocol assistance consultations.</p><p>This represents a cultural shift. Regulators aren’t waiting for AI applications to arrive in submission packages — they want to <strong>co-develop the validation standards</strong> with industry.</p><p><strong>Strategic implication</strong>: Early regulatory engagement is no longer a defensive move to de-risk borderline applications. It’s an <strong>offensive strategy</strong> to shape the interpretation of guidance in your favor.</p><h3>Five Market Opportunities Created by These Policies</h3><h3>Opportunity #1: Precision Medicine Goes Mainstream</h3><p><strong>The opening</strong>: Both documents explicitly endorse AI for identifying treatment-effect modifiers and biomarker-driven patient selection.</p><p><strong>Why now</strong>: Sponsors have been hesitant to commit to biomarker-enriched trials without regulatory confidence that the approach would be accepted. These policies provide that confidence.</p><p><strong>What to build</strong>: AI tools for post-hoc subgroup discovery that meet prospective validation standards, enrichment strategy optimization for basket and umbrella trials, and adaptive biomarker-driven randomization algorithms.</p><p><strong>Market size</strong>: Every oncology, immunology, and rare disease trial is a potential customer. This is a multi-billion dollar TAM.</p><h3>Opportunity #2: Digital Endpoints Get Regulatory Legitimacy</h3><p><strong>The opening</strong>: The EMA specifically addresses AI-derived endpoints from wearables, imaging, and patient-reported outcomes. The FDA’s framework accommodates novel measurement tools.</p><p><strong>Why now</strong>: The decentralized trial movement created demand; regulatory acceptance removes the final barrier.</p><p><strong>What to build</strong>: Validated models converting wearable data (activity, sleep, vitals) into clinical endpoints, computer vision algorithms for at-home imaging or gait analysis, and natural language processing for patient diary interpretation with FDA-grade reliability.</p><p><strong>Market size</strong>: Every therapeutic area seeking remote monitoring or patient-centric endpoints.</p><h3>Opportunity #3: Real-World Evidence Analysis at Scale</h3><p><strong>The opening</strong>: FDA has a dedicated RWE program for AI applications; EMA discusses registry studies and post-market surveillance.</p><p><strong>Why now</strong>: COVID-19 proved that RWE can support regulatory decisions. AI makes RWD scalable.</p><p><strong>What to build</strong>: AI-powered external control arms using historical data, synthetic control generation with provable covariate balance, post-market safety signal detection with interpretable alerting, and EHR data curation and harmonization at multi-site scale.</p><p><strong>Market size</strong>: Every label expansion, indication extension, and post-market requirement study.</p><h3>Opportunity #4: Trial Optimization Without Regulatory Risk</h3><p><strong>The opening</strong>: Both documents accept AI for trial design, site selection, and operational optimization as “lower influence” applications with proportionally lighter validation requirements.</p><p><strong>Why now</strong>: Sponsors are desperate to reduce the 50% screen failure rates and 30% site underperformance plaguing modern trials.</p><p><strong>What to build</strong>: Patient recruitment likelihood prediction with site-level forecasting, eligibility criteria optimization showing impact on enrollment speed, site selection algorithms incorporating historical performance data, and retention risk prediction with targeted intervention workflows.</p><p><strong>Market size</strong>: Applied to every trial, even with modest pricing, this is enormous.</p><h3>Opportunity #5: Manufacturing and Quality Control AI</h3><p><strong>The opening</strong>: FDA dedicates substantial coverage to AI in pharmaceutical manufacturing, from visual inspection to process analytics.</p><p><strong>Why now</strong>: Continuous manufacturing adoption creates demand for real-time quality assurance.</p><p><strong>What to build</strong>: Computer vision for tablet defect detection, process analytical technology (PAT) AI for in-line quality monitoring, and batch release decision support with traceable reasoning.</p><p><strong>Market size</strong>: Every pharmaceutical manufacturer with visual inspection or process monitoring needs.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*ZvYSXeADafbCENMwxTj8Yw.png" /></figure><p><strong>Figure 4.1.</strong> Five Major Market Opportunities for AI Companies in Clinical Trials</p><h3>What Winning Companies Will Do Differently</h3><h3>Build Compliance Into the Product, Not Around It</h3><p>The highest-performing AI companies in clinical trials will be those that treat regulatory requirements as <strong>product features</strong>, not compliance burdens.</p><p><strong>Specific implementations</strong>: Automated generation of COU documentation aligned with FDA’s five-step framework, one-click model freezing with blockchain-style immutability verification, real-time bias monitoring dashboards showing performance across subgroups, and explainability reports generated automatically for every model inference.</p><p><strong>Why this wins</strong>: Sponsors don’t want AI tools plus compliance headaches. They want “regulatory-ready” solutions that reduce review cycles.</p><h3>Establish Regulatory Relationships Early</h3><p>Companies that engage FDA and EMA <strong>before</strong> they have specific submission needs will shape the interpretation of these still-evolving guidances.</p><p><strong>Tactical moves</strong>: Request Type C meetings to discuss your platform’s validation approach generally, join the CATT program and present at FDA workshops, contribute to industry working groups (DIA, CTTI, C-Path) developing AI standards, and publish methodology papers in peer-reviewed journals that regulators cite.</p><p><strong>Why this wins</strong>: Regulators are more receptive to novel approaches from known quantities than from first-time interlocutors.</p><h3>Invest in Prospective Validation Infrastructure</h3><p>Retrospective performance metrics won’t cut it for high-stakes applications. You need infrastructure to validate models on <strong>future calendar-time data</strong> in the target population.</p><p><strong>What this requires</strong>: Temporal holdout strategies that preserve time ordering, partnerships for prospective data collection (registries, observational cohorts), simulation environments for stress-testing models under distribution shift, and continuous monitoring systems that detect degradation before it impacts patients.</p><p><strong>Why this wins</strong>: Sponsors won’t take regulatory risk on models validated only on historical splits.</p><h3>Differentiate on Explainability and Trust</h3><p>“Black box AI” is a non-starter for high-influence applications. But explainability isn’t binary — it’s a spectrum. Winners will offer <strong>fit-for-purpose transparency</strong> matched to context of use.</p><p><strong>Implementation spectrum</strong>: — <strong>Exploratory models</strong>: Feature importance and decision boundaries — <strong>Corroborative models</strong>: Attention maps and similar-case comparisons — <strong>Direct-influence models</strong>: Full causal reasoning chains and counterfactual analysis</p><p><strong>Why this wins</strong>: Regulators can’t approve what they can’t understand. Your model’s scientific logic must be defensible.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/405/1*2lkKUa1q618AEFT53IPuiw.png" /></figure><p><strong>Figure 5.1.</strong> Essential Components of a Regulatory-Ready AI Platform</p><h3>The Three Traps to Avoid</h3><h3>Trap #1: Treating These as “Final” Guidance</h3><p>These are <strong>draft</strong> (FDA) and <strong>reflection</strong> (EMA) papers — meaning the requirements will evolve. Companies that implement the minimum requirements rigidly will need expensive retrofits.</p><p><strong>Better approach</strong>: Build flexible systems that can adapt as requirements tighten. Over-invest in audit trails and documentation infrastructure.</p><h3>Trap #2: Assuming Regulation Equals Barrier</h3><p>The companies treating these policies as obstacles will lose to those recognizing them as <strong>market validation</strong>. Regulation signals that AI has crossed the threshold from “experimental” to “mission-critical.”</p><p><strong>Better approach</strong>: Position your regulatory preparedness as competitive advantage, not cost center.</p><h3>Trap #3: Ignoring the Global Picture</h3><p>FDA and EMA are aligned on principles but divergent on specifics. Building for only one market limits your addressable opportunity.</p><p><strong>Better approach</strong>: Design for the strictest requirements (often EMA), which will satisfy both regulators.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*PyOhN8I3BQVvA7tAL2cFDA.png" /></figure><p><strong>Figure 6.1.</strong> Strategic Choices That Determine Market Position</p><h3>The Bottom Line: This Is Your Market Moment</h3><p>For the past decade, AI in clinical trials has been stuck in pilot purgatory — promising demos that never scaled to regulatory-grade applications. These policies end that era.</p><p>What regulators are saying is: <strong>“We’re ready for AI. The question is, are you ready for regulation?”</strong></p><p>The next 24 months will separate companies that seized this moment from those that hesitated:</p><p>✅ <strong>Winners</strong> will launch “regulatory-ready” platforms that generate FDA/EMA-compliant documentation automatically</p><p>✅ <strong>Winners</strong> will secure early regulatory feedback that shapes their product roadmap</p><p>✅ <strong>Winners</strong> will target the highest-value use cases (precision medicine, digital endpoints, RWE) where regulatory clarity creates sponsor urgency</p><p>❌ <strong>Losers</strong> will treat compliance as an afterthought, retrofit documentation, and struggle with regulatory pushback</p><p>❌ <strong>Losers</strong> will wait for “more guidance” while first-movers capture market share</p><p>❌ <strong>Losers</strong> will underinvest in validation infrastructure and fail to meet prospective testing standards</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*XxeWQ1YAD6apDbLoxO-g-A.png" /></figure><p><strong>Figure 7.1.</strong> The AI Clinical Trial Lifecycle: Key Gates and Requirements</p><h3>Your Next Steps</h3><p>If you’re leading an AI company in the clinical trials space, here’s your 90-day playbook:</p><p><strong>Week 1–2: Executive alignment</strong> — Share this analysis with your leadership team and board — Decide if “regulatory-ready AI” will be a core differentiator or table stakes — Allocate budget for compliance infrastructure (it’s product development, not overhead)</p><p><strong>Week 3–6: Gap assessment</strong> — Audit your current platform against FDA’s five-step framework and EMA requirements — Identify which features enable pivotal trial applications vs. exploratory use only — Prioritize model freezing, prospective validation, and explainability capabilities</p><p><strong>Week 7–12: Build and engage</strong> — Implement automated COU documentation and credibility assessment — Request FDA pre-submission meeting (Type C or CATT) — Publish methodology white papers establishing your scientific credibility — Update marketing materials to emphasize regulatory readiness</p><p>The clinical trials AI market just got its regulatory blueprint. Companies that treat these policies as strategic assets — not compliance burdens — will dominate the decade ahead.</p><p><strong>The window is open. The framework is clear. The opportunity is massive.</strong></p><p><em>What will you build?</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*NFFpgJ9LpGlx5bNapgwkxw.png" /></figure><p><strong>Figure 8.1.</strong> Navigating FDA and EMA Engagement Options for AI Companies</p><h3>About These Policies</h3><p><a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological">· <strong>FDA Draft Guidance</strong></a>: “Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products” (January 2025) — Comments due 60 days after Federal Register publication</p><p><a href="https://www.ema.europa.eu/en/use-artificial-intelligence-ai-medicinal-product-lifecycle-scientific-guideline">· <strong>EMA Reflection Paper</strong></a>: “Use of Artificial Intelligence (AI) in the Medicinal Product Lifecycle” (September 2024, EMA/399216/2023)</p><p>Both documents are available publicly and represent current regulatory thinking on AI in drug development. While draft/reflection papers aren’t binding requirements, they signal agency expectations and should inform platform development strategies.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=6049d1d53c11" width="1" height="1" alt=""><hr><p><a href="https://medium.com/keiji-ai/the-ai-regulation-revolution-how-new-fda-and-ema-guidance-opens-the-clinical-trials-market-6049d1d53c11">The AI Regulation Revolution: How New FDA and EMA Guidance Opens the Clinical Trials Market</a> was originally published in <a href="https://medium.com/keiji-ai">Keiji AI</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Understanding AI’s New Power Duo: MCP and Claude Skills]]></title>
            <link>https://medium.com/keiji-ai/understanding-ais-new-power-duo-mcp-and-claude-skills-bd0f017b185f?source=rss-5c0308f333cc------2</link>
            <guid isPermaLink="false">https://medium.com/p/bd0f017b185f</guid>
            <category><![CDATA[mcp-server]]></category>
            <category><![CDATA[claude-skills]]></category>
            <category><![CDATA[trialmind]]></category>
            <dc:creator><![CDATA[Jimeng]]></dc:creator>
            <pubDate>Mon, 17 Nov 2025 15:00:22 GMT</pubDate>
            <atom:updated>2025-11-18T04:41:18.181Z</atom:updated>
            <content:encoded><![CDATA[<p>Jimeng Sun, Keiji AI | UIUC</p><h3>The Missing Pieces in AI Integration</h3><p>Imagine you’re building the perfect AI assistant for your organization. You have cutting-edge language models that can reason, write, and analyze. But there’s a problem: your AI is like a brilliant consultant locked in a soundproof room with no internet, no access to your company’s databases, and no knowledge of your company’s specific workflows.</p><p>This is the reality most organizations face when implementing AI. The models are powerful, but they’re isolated islands — disconnected from the enterprise data and domain expertise that make them truly useful.</p><p>Enter two complementary innovations from Anthropic: <strong>Model Context Protocol (MCP)</strong> and <strong>Claude Skills</strong>. Together, they’re transforming isolated AI models into connected, knowledgeable agents that can actually get work done.</p><p><strong>A Critical Clarification:</strong> While we’ll discuss MCP and Skills through Anthropic’s implementation, these are <strong>open architectural concepts, not proprietary software</strong>. MCP is an open standard that any AI system can adopt. The underlying principles — standardized data connectivity and modular knowledge packages — can be implemented in any AI agent pipeline, whether you’re using OpenAI, open-source models, or building your own proprietary system. This article explores the ideas and patterns that make AI agents effective, not specific vendor solutions. For example, at Keiji AI, we implemented these concepts via our own MCP servers and Skills (secure sandbox, tool calling and guidance memory).</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*BamTFaGb4lIIww-CsEpoBA.png" /><figcaption><strong>Transformation from Isolated AI to Connected Intelligence</strong></figcaption></figure><h3>What is MCP? Your AI’s Universal Data Port</h3><p>Think of MCP as a USB-C port for AI applications. Just as USB-C created a universal standard for connecting devices, MCP creates a universal standard for connecting AI to data sources.</p><p>Before MCP, every time you wanted to connect your AI to a new data source — whether that’s your company’s database, GitHub repositories, or a CRM system — you needed custom code. A separate integration for each connection. It was like needing a different cable for every device you own.</p><h3>The Old Way: Custom Integration Nightmare</h3><pre>ChatGPT ─────────────┐<br>       │             │<br>   Custom Code   Custom Code<br>       │             │<br>       ▼             ▼<br>    Database      GitHub<br></pre><pre>    Claude ──────────┐<br>       │             │<br>   Custom Code   Custom Code<br>       │             │<br>       ▼             ▼<br>    Database      GitHub<br></pre><pre>    Gemini ──────────┐<br>       │             │<br>   Custom Code   Custom Code<br>       │             │<br>       ▼             ▼<br>    Database      GitHub</pre><pre>Result: 3 AI models × 2 data sources = 6 custom integrations!</pre><h3>The MCP Way: Plug and Play</h3><pre>   ChatGPT  ────┐<br>                │<br>    Claude ─────┼──── MCP Protocol ────┐<br>                │                      │<br>    Gemini. ────┘                      │<br>                                       ▼<br>                               ┌──────────────┐<br>                               │ MCP Server   │<br>                               │  (Database)  │<br>                               └──────────────┘<br>                                      │<br>                               ┌──────────────┐<br>                               │ MCP Server   │<br>                               │   (GitHub)   │<br>                               └──────────────┘</pre><pre>Result: Build each MCP server once, any AI can connect!</pre><p>MCP changes this by providing a standardized protocol. Build one MCP server for your data source, and any MCP-compatible AI application can connect to it. It’s a shift from “N×M problem” (every AI needing integration with every data source) to a “plug-and-play” ecosystem.</p><h3>The Three Building Blocks</h3><p>MCP defines three core concepts that make this work:</p><pre>┌─────────────────────────────────────────────────────┐<br>│                   MCP HOST                          │<br>│              (Claude Desktop, IDE)                  │<br>│                                                     │<br>│  ┌──────────────────────────────────────────────┐  │<br>│  │            MCP CLIENT                        │  │<br>│  │      (Manages connections &amp; security)        │  │<br>│  └──────────────────┬───────────────────────────┘  │<br>└─────────────────────┼──────────────────────────────┘<br>                      │<br>        ┌─────────────┼─────────────┐<br>        │             │             │<br>        ▼             ▼             ▼<br>   ┌─────────┐   ┌─────────┐   ┌───────────┐<br>   │   MCP   │   │   MCP   │   │   MCP     │<br>   │ Server  │   │ Server  │   │ Server    │<br>   │(GitHub) │   │ (Slack) │   │(TrialMind)│<br>   └────┬────┘   └────┬────┘   └────┬──────┘<br>        │             │             │<br>        │             │             │<br>   RESOURCES      TOOLS         PROMPTS<br>   <br>   Documents      Query DB      Templates<br>   API Data       Search Web    Instructions<br>   Files          Send Message  Guides</pre><p><strong>Resources</strong> are the data itself — documents, database records, API responses. Think of these as the content your AI can read from.</p><p><strong>Tools</strong> are actions your AI can take — querying a database, searching the web, updating a record. These are the verbs in your AI’s vocabulary.</p><p><strong>Prompts</strong> are pre-configured instructions that guide how your AI interacts with these resources and tools.</p><h3>Why This Matters</h3><p>The power of MCP lies in its standardization. When a company builds an MCP server for their proprietary system, it works not just with Claude, but with any AI application that supports MCP. OpenAI, Google DeepMind, and major development tools like VS Code and Replit are all adopting it.</p><p>More importantly, MCP includes built-in logging and audit trails — critical for regulated industries where every AI decision needs to be traceable.</p><h3>What are Claude Skills? Teaching AI Your Way of Working</h3><p>If MCP is about connecting to data, Skills are about teaching expertise. They’re modular packages that encode your organization’s specific knowledge, workflows, and best practices.</p><p>Here’s the key insight: having access to data isn’t enough. Your AI also needs to know <strong>how</strong> to use that data according to your workflows.</p><p>Imagine you’re onboarding a new clinical research associate to run a clinical trial. You don’t just give them access to all your systems and hope for the best. You teach them your methodology — how to structure reports, which metrics matter, what quality standards to meet, and the step-by-step process for different types of analysis.</p><p>Skills do the same for AI.</p><h3>How Skills Work</h3><p>A Skill is a simple package containing:</p><ul><li><strong>Instructions</strong> written in plain Markdown that explain the workflow</li><li><strong>Scripts</strong> for repetitive or complex calculations</li><li><strong>Templates</strong> for consistent output formatting</li><li><strong>References</strong> for domain-specific knowledge</li></ul><pre>┌───────────────────────────────────────────────┐<br>│         SKILL PACKAGE STRUCTURE               │<br>│                                               │<br>│  📄 SKILL.md (Required)                       │<br>│     ├─ name: &quot;sales-report&quot;                   │<br>│     ├─ description: &quot;When to use this&quot;        │<br>│     └─ Instructions: &quot;How to do it&quot;           │<br>│                                               │<br>│  📁 scripts/ (Optional)                       │<br>│     └─ calculate_metrics.py                   │<br>│                                               │<br>│  📁 references/ (Optional)                    │<br>│     └─ metrics_glossary.md                    │<br>│                                               │<br>│  📁 assets/ (Optional)                        │<br>│     └─ report_template.docx                   │<br>└───────────────────────────────────────────────┘</pre><p>The genius is in the <strong>progressive disclosure</strong>:</p><pre>Step 1: Claude scans ALL Skill metadata<br>        ↓<br>   ┌─────────────────────────────┐<br>   │ &quot;sales-report&quot; - relevant!  │<br>   │ &quot;legal-review&quot; - not needed │<br>   │ &quot;code-audit&quot; - not needed   │<br>   └─────────────────────────────┘</pre><pre>Step 2: Load ONLY the relevant Skill<br>        ↓<br>   ┌──────────────────────┐<br>   │  SKILL.md loaded     │<br>   │  (Instructions)      │<br>   └──────────────────────┘</pre><pre>Step 3: Access resources AS NEEDED<br>        ↓<br>   ┌──────────────────────┐<br>   │  Run script when     │<br>   │  calculations needed │<br>   │                      │<br>   │  Load template when  │<br>   │  formatting report   │<br>   └──────────────────────┘</pre><pre>Result: Token-efficient, only load what you need!</pre><p>Claude doesn’t load every Skill into memory all the time. Instead, it scans Skill descriptions, identifies which ones are relevant to your current task, and loads only what’s needed. This keeps things token-efficient while making expertise available on demand.</p><h3>Real-World Impact</h3><p>A marketing team might create a “competitive-analysis” Skill that defines their exact methodology for evaluating competitors. A legal team might build a “contract-review” Skill that encodes their checklist and risk assessment framework. A data science team might create a “model-validation” Skill that ensures consistent statistical practices.</p><p>Once created, these Skills can be shared across the entire organization, ensuring everyone — or rather, every AI interaction — follows the same standards.</p><h3>The Real Power: MCP + Skills Together</h3><p>Here’s where it gets interesting. MCP and Skills aren’t alternatives — they’re designed to work together. Next, we will show some examples of how TrialMind (an AI agent from Keiji AI) utilizes these two concepts (MCP + Skills) for supporting clinical research and running clinical trials.</p><pre>┌─────────────────────────────────────────────────────────────┐<br>│  USER REQUEST: &quot;Create feasibility report for Phase 2 trial&quot; │<br>└────────────────────────┬────────────────────────────────────┘<br>                         │<br>                         ▼<br>        ┌────────────────────────────────────┐<br>        │  TrialMind identifies relevant Skill  │<br>        │  &quot;clinical-feasibility-analysis&quot;   │<br>        └────────┬───────────────────────────┘<br>                 │<br>                 ▼<br>    ┌────────────────────────────────────────────┐<br>    │         SKILL PROVIDES:                    │<br>    │  ✓ Report structure                        │<br>    │  ✓ Analysis methodology                    │<br>    │  ✓ Quality standards                       │<br>    │  ✓ Compliance requirements                 │<br>    │  ✓ Output template                         │<br>    └────────┬───────────────────────────────────┘<br>             │<br>             │  Following Skill&#39;s workflow...<br>             │<br>             ▼<br>    ┌─────────────────────────────────────┐<br>    │    MCP CONNECTIONS ACTIVATE:        │<br>    │                                     │<br>    │  ┌─────────────┐  ┌─────────────┐  │<br>    │  │ EHR Server  │  │PubMed Server│  │<br>    │  │             │  │             │  │<br>    │  │ TOOL:       │  │ TOOL:       │  │<br>    │  │ query_ehr   │  │ lit_search  │  │<br>    │  └──────┬──────┘  └──────┬──────┘  │<br>    │         │                │         │<br>    │  ┌──────▼────────────────▼──────┐  │<br>    │  │  Patient    Literature       │  │<br>    │  │  Cohorts    Review           │  │<br>    │  └──────────────────────────────┘  │<br>    └──────────┬──────────────────────────┘<br>               │<br>               │  All queries logged for audit<br>               │<br>               ▼<br>    ┌──────────────────────────────────────┐<br>    │    SKILL GUIDES SYNTHESIS:           │<br>    │  • Apply statistical models          │<br>    │  • Calculate recruitment estimates   │<br>    │  • Format using template             │<br>    │  • Ensure regulatory compliance      │<br>    └──────────┬───────────────────────────┘<br>               │<br>               ▼<br>    ┌──────────────────────────────────────┐<br>    │    OUTPUT: GxP-Compliant Report      │<br>    │  ✓ Complete audit trail              │<br>    │  ✓ Consistent format                 │<br>    │  ✓ Regulatory-ready                  │<br>    │  ✓ Reproducible                      │<br>    └──────────────────────────────────────┘KEY:<br>MCP = Data Access Layer (connects to external systems)<br>Skills = Knowledge Layer (defines how to use that data)<br>Together = Complete, compliant AI workflow</pre><p>Let me illustrate with a real-world example that’s transforming one of the most regulated, high-stakes industries: pharmaceutical research.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*LVPvTcYC4gJIrjZsbBLALQ.png" /></figure><h3>Case Study: TrialMind and Clinical Research</h3><p>Pharmaceutical companies face a brutal reality: they spend over $50 billion annually on clinical trials, yet 90% of those trials fail. A major reason is the fragmentation of data. Critical information is scattered across:</p><pre>THE DATA FRAGMENTATION PROBLEM:</pre><pre>        Research Question: &quot;Is this trial feasible?&quot;<br>                           │<br>        ┌──────────────────┼──────────────────┐<br>        │                  │                  │<br>        ▼                  ▼                  ▼<br>   ┌─────────┐       ┌─────────┐       ┌─────────┐<br>   │ PubMed  │       │ Clinical│       │   EHR   │<br>   │         │       │Trials.  │       │ Systems │<br>   │Literature│      │  gov    │       │         │<br>   └─────────┘       └─────────┘       └─────────┘<br>        │                  │                  │<br>   Requires          Requires          Requires<br>   custom API        web scraping      HL7/FHIR<br>                          │<br>        ┌─────────────────┼─────────────────┐<br>        │                 │                 │<br>        ▼                 ▼                 ▼<br>   ┌─────────┐       ┌─────────┐       ┌─────────┐<br>   │ CDISC/  │       │ Genomic │       │Internal │<br>   │  OMOP   │       │  Repos  │       │  Data   │<br>   │Databases│       │         │       │         │<br>   └─────────┘       └─────────┘       └─────────┘<br>        │                 │                 │<br>   Requires          Requires          Requires<br>   regulatory        bioinfor-         proprietary<br>   standards         matics tools      protocols</pre><pre>RESULT: Weeks of integration work for each data source<br>        No audit trails, compliance nightmares<br>        Researchers spend more time on data access than analysis</pre><ul><li>Scientific literature databases like PubMed</li><li>Trial registries like ClinicalTrials.gov</li><li>Electronic Health Records at thousands of hospitals</li><li>Regulatory databases using standards like CDISC and OMOP</li><li>Genomic repositories</li><li>Internal experimental data</li></ul><p>Traditionally, accessing each system required custom code, specialized query languages, and weeks of integration work. More importantly, in healthcare, every query must be logged for regulatory compliance. The FDA and EMA demand complete traceability.</p><h3>Enter TrialMind</h3><p>TrialMind, developed by Keiji AI, uses MCP and Skills to transform clinical research workflows.</p><p><strong>An Important Note on Implementation:</strong> While we’ve been discussing MCP and Skills in the context of Anthropic’s Claude, it’s crucial to understand that <strong>these are architectural concepts and design patterns, not proprietary software locked to a single vendor</strong>. MCP is an open standard that can be implemented in any AI agent pipeline. The core ideas — secure sandboxed environments, standardized tool calling, and modular knowledge packages — are universal principles for building robust AI agent workflows.</p><pre>THE CONCEPTS ARE UNIVERSAL - MULTIPLE IMPLEMENTATIONS:</pre><pre>┌─────────────────────────────────────────────────────────┐<br>│        CORE ARCHITECTURAL CONCEPTS                      │<br>│  • Standardized tool calling interface                  │<br>│  • Secure sandboxed execution                           │<br>│  • Modular knowledge packages                           │<br>│  • Audit logging &amp; traceability                         │<br>└───────────────────┬─────────────────────────────────────┘<br>                    │<br>        ┌───────────┼───────────┐<br>        │           │           │<br>        ▼           ▼           ▼<br>┌──────────┐  ┌──────────┐  ┌──────────┐<br>│Anthropic │  │ Keiji AI │  │   Your   │<br>│  Claude  │  │TrialMind │  │ Custom   │<br>│          │  │          │  │ Platform │<br>└────┬─────┘  └────┬─────┘  └────┬─────┘<br>     │             │             │<br>     ├─ Official   ├─ Custom     ├─ Your own<br>     │  MCP impl.  │  impl. of   │  impl. of<br>     │             │  same ideas │  concepts<br>     ├─ Skills     ├─ Domain-    ├─ Adapted<br>     │  system     │  specific   │  for your<br>     │             │  modules    │  needs<br>     │             │             │<br>     ▼             ▼             ▼<br>  Works with   Works with    Works with<br>  general AI   clinical      your domain<br>  tasks        research      workflows</pre><pre>SAME PRINCIPLES, DIFFERENT IMPLEMENTATIONS</pre><p>At Keiji AI, we implemented our own TrialMind AI agent platform using these same fundamental concepts (secure sandbox + tool calling + modular expertise) specifically optimized for clinical research and clinical trial applications. You don’t need to use Claude or Anthropic’s specific implementations. Whether you’re building with OpenAI, open-source models, or proprietary systems, the architectural patterns of separating data connectivity from domain expertise remain powerful and applicable.</p><p>This is about <strong>how to think about AI agent architecture</strong>, not about which vendor to choose.</p><pre>THE MCP SOLUTION:</pre><pre>   Researcher asks in natural language:<br>   &quot;Find protein XYZ inhibitors from last 5 years&quot;<br>                    │<br>                    ▼<br>        ┌───────────────────────┐<br>        │   TRIALMIND AGENT     │<br>        │   (Powered by Claude) │<br>        └───────────┬───────────┘<br>                    │<br>                    │ Uses MCP Protocol<br>                    │<br>        ┌───────────┼───────────┐<br>        │           │           │<br>        ▼           ▼           ▼<br>   ┌─────────┐ ┌─────────┐ ┌─────────┐<br>   │   MCP   │ │   MCP   │ │   MCP   │<br>   │ Server  │ │ Server  │ │ Server  │<br>   │ PubMed  │ │  EHR    │ │Clinical │<br>   │         │ │         │ │Trials   │<br>   └────┬────┘ └────┬────┘ └────┬────┘<br>        │           │           │<br>        │ All connections logged &amp; audited<br>        │<br>        ▼<br>   ┌─────────────────────────────────┐<br>   │   Standardized Data Access      │<br>   │   • Literature search           │<br>   │   • Patient cohort queries      │<br>   │   • Trial registry searches     │<br>   │   • Full audit trails           │<br>   │   • Regulatory compliance       │<br>   └─────────────────────────────────┘</pre><pre>BENEFITS:<br>✓ Natural language queries (no SQL/APIs to learn)<br>✓ Automatic audit logging for FDA/EMA<br>✓ Days instead of weeks for integration<br>✓ One protocol, many data sources</pre><p><strong>The MCP Layer:</strong> TrialMind built their own implementation of the MCP concepts — specialized servers and tool-calling infrastructure for each clinical data source. They created a PubMed integration for literature searches, an EHR connector for patient data, and interfaces with clinical trial registries. While inspired by the MCP standard, this is Keiji AI’s own infrastructure optimized for the unique security, compliance, and performance requirements of clinical research.</p><p>The key innovation isn’t which specific software they used, but <strong>how they architected the system</strong>: standardized tool interfaces, secure sandboxed execution, and comprehensive audit logging — the core principles that make MCP powerful.</p><p>Here’s what this enables:</p><p>A researcher can simply ask: <strong>“Find inhibitors of protein XYZ reported in the last 5 years”</strong></p><p>Behind the scenes, Claude invokes the PubMed MCP server, which handles all the complexity of querying the database with the right API calls and data formats. The researcher gets current, cited results without visiting any websites or learning query syntax.</p><p>Or consider: <strong>“How many patients in our EHR system meet the exclusion criteria for Trial XYZ?”</strong></p><p>The EHR MCP server queries the clinical database, applies the criteria, and returns patient cohorts with recruitment estimates and visualizations. All while automatically logging every query for FDA compliance.</p><p><strong>The Skills Layer:</strong> But data access alone isn’t enough. TrialMind also created Skills that encode validated research methodologies.</p><p>A “clinical-feasibility-analysis” Skill defines the exact workflow for evaluating whether a trial is viable:</p><ol><li>Review protocol inclusion/exclusion criteria</li><li>Query patient populations via MCP</li><li>Analyze competitive landscape through trial registries</li><li>Review current literature for treatment standards</li><li>Generate a report using regulatory-approved templates</li><li>Ensure all data access is logged for audit trails</li></ol><p>The Skill provides the <strong>methodology</strong>. The MCP connections provide the <strong>data</strong>. Together, they enable something remarkable.</p><h3>The Transformation</h3><p>A clinical researcher can now ask in plain language: <strong>“Create a feasibility report for our Phase 2 oncology trial”</strong></p><p>The system:</p><ol><li>Loads the appropriate Skill (defines what a good feasibility report looks like)</li><li>Activates relevant MCP connections (accesses real patient data, literature, trial registries)</li><li>Follows the Skill’s workflow (applies the right analytical framework)</li><li>Generates a report that’s regulatory-ready with full audit trails</li></ol><p>What previously took weeks of custom queries, manual data gathering, and Excel manipulation now happens in minutes — with better compliance than manual processes.</p><h3>Why This Matters for Regulated Industries</h3><p>The TrialMind example reveals why the MCP + Skills combination is particularly powerful for healthcare, finance, legal, and other regulated sectors:</p><p><strong>Auditability</strong>: Every MCP tool call is automatically logged. Regulatory reviewers can trace every piece of data used in a decision back to its source.</p><p><strong>Reproducibility</strong>: The combination of logged data access and documented workflows means analyses can be exactly reproduced — critical for regulatory submissions.</p><p><strong>Compliance by Design</strong>: Rather than hoping users follow procedures, the procedures are encoded into Skills that guide every interaction. We can also separate code generation (AI layer) from code execution (secure data layer).</p><p><strong>Speed Without Chaos</strong>: Integration that used to take weeks now takes days, but with more control and oversight than custom integrations typically provided.</p><h3>The Bigger Picture: A New Architecture for AI</h3><p>What MCP and Skills represent is a fundamental shift in how we think about AI integration.</p><pre>OLD MODEL: Monolithic &amp; Brittle<br>┌─────────────────────────────────────────────┐<br>│        Custom AI Application                │<br>│                                             │<br>│  ┌──────────────────────────────────────┐  │<br>│  │  Hardcoded Integrations              │  │<br>│  │  • Database connection code          │  │<br>│  │  • API client implementations        │  │<br>│  │  • Authentication logic              │  │<br>│  │  • Data transformation               │  │<br>│  └──────────────────────────────────────┘  │<br>│                                             │<br>│  ┌──────────────────────────────────────┐  │<br>│  │  Massive System Prompt               │  │<br>│  │  • Domain knowledge                  │  │<br>│  │  • Workflows &amp; procedures            │  │<br>│  │  • Examples &amp; templates              │  │<br>│  │  • Quality standards                 │  │<br>│  └──────────────────────────────────────┘  │<br>│                                             │<br>│  ┌──────────────────────────────────────┐  │<br>│  │  AI Model                            │  │<br>│  │  (Everything tightly coupled)        │  │<br>│  └──────────────────────────────────────┘  │<br>└─────────────────────────────────────────────┘</pre><pre>Problems:<br>❌ Hard to maintain (one big codebase)<br>❌ Can&#39;t reuse components across projects<br>❌ Difficult to update (change one thing, risk breaking everything)<br>❌ No audit trails<br>❌ Vendor lock-in<br></pre><pre>NEW MODEL: Modular &amp; Composable<br>┌─────────────────────────────────────────────┐<br>│           AI Application                    │<br>│                                             │<br>│  ┌──────────────────────────────────────┐  │<br>│  │         AI Model (Claude)            │  │<br>│  │           Orchestrator               │  │<br>│  └───┬──────────────────────────────┬───┘  │<br>│      │                              │      │<br>│      ▼                              ▼      │<br>│  ┌─────────┐                  ┌─────────┐  │<br>│  │   MCP   │                  │ Skills  │  │<br>│  │ Protocol│                  │ System  │  │<br>│  │         │                  │         │  │<br>│  │ Data    │                  │Domain   │  │<br>│  │ Access  │                  │Expertise│  │<br>│  └────┬────┘                  └────┬────┘  │<br>│       │                            │       │<br>└───────┼────────────────────────────┼───────┘<br>        │                            │<br>        ▼                            ▼<br>   ┌─────────┐                 ┌─────────┐<br>   │  MCP    │                 │ Skill   │<br>   │Servers  │                 │Packages │<br>   │         │                 │         │<br>   │• GitHub │                 │•Reports │<br>   │• Slack  │                 │•Analysis│<br>   │• CRM    │                 │•Reviews │<br>   │(Reusable│                 │(Portable│<br>   │  across │                 │ &amp; Share-│<br>   │   AIs)  │                 │  able)  │<br>   └─────────┘                 └─────────┘</pre><pre>Benefits:<br>✓ Modular (update parts independently)<br>✓ Reusable (Skills &amp; MCP servers work across projects)<br>✓ Auditable (MCP logs everything)<br>✓ Flexible (swap components as needed)<br>✓ No vendor lock-in (open standards)</pre><p><strong>The Old Model</strong> was monolithic: build a custom AI application with hard-coded integrations and hope your prompt engineering captures all the domain knowledge.</p><p><strong>The New Model</strong> is modular and composable:</p><ul><li>MCP provides standardized data connectivity</li><li>Skills provide portable domain expertise</li><li>AI models orchestrate between them</li></ul><p>This architecture solves several critical problems:</p><p><strong>The Integration Problem</strong>: Instead of N×M custom integrations (every AI with every data source), you build once using MCP standards.</p><p><strong>The Knowledge Problem</strong>: Instead of embedding expertise in impossible-to-maintain prompts, you encode it in shareable, versionable Skills.</p><p><strong>The Compliance Problem</strong>: Instead of hoping AI behaves correctly, you build guardrails into the architecture itself through logged MCP calls and validated Skills.</p><p><strong>The Scaling Problem</strong>: Adding new data sources or capabilities becomes dramatically easier when you’re working with standards rather than custom code.</p><h3>What This Means for Your Organization</h3><p>If you’re considering AI implementation, the MCP + Skills framework offers a practical path forward:</p><pre>IMPLEMENTATION ROADMAP:</pre><pre>Phase 1: Start with MCP<br>┌──────────────────────────────────────┐<br>│  Identify 3-5 Critical Data Sources  │<br>│  • CRM (Salesforce, HubSpot)         │<br>│  • Databases (PostgreSQL, MongoDB)   │<br>│  • Document repos (Google Drive)     │<br>│  • APIs (GitHub, Slack)              │<br>└────────────┬─────────────────────────┘<br>             │<br>             ▼<br>┌──────────────────────────────────────┐<br>│  Build or Use Existing MCP Servers   │<br>│  Time: Days to weeks per server      │<br>└────────────┬─────────────────────────┘<br>             │<br>             ▼<br>        Test &amp; Validate<br>             │<br>             │<br>Phase 2: Develop Skills<br>             │<br>             ▼<br>┌──────────────────────────────────────┐<br>│  Document Key Workflows              │<br>│  Work with domain experts:           │<br>│  • Report generation                 │<br>│  • Data analysis procedures          │<br>│  • Compliance checks                 │<br>│  • Quality standards                 │<br>└────────────┬─────────────────────────┘<br>             │<br>             ▼<br>┌──────────────────────────────────────┐<br>│  Create Skill Packages               │<br>│  • Write workflows in Markdown       │<br>│  • Add scripts for calculations      │<br>│  • Include templates                 │<br>│  Time: Days per skill                │<br>└────────────┬─────────────────────────┘<br>             │<br>             ▼<br>        Test &amp; Refine<br>             │<br>             │<br>Phase 3: Combine &amp; Scale<br>             │<br>             ▼<br>┌──────────────────────────────────────┐<br>│  Deploy End-to-End AI Agents         │<br>│  • Data access via MCP               │<br>│  • Workflows via Skills              │<br>│  • AI orchestrates both              │<br>└────────────┬─────────────────────────┘<br>             │<br>             ▼<br>┌──────────────────────────────────────┐<br>│  RESULT:                             │<br>│  ✓ Connected AI with data access     │<br>│  ✓ Knowledgeable AI with expertise   │<br>│  ✓ Compliant AI with audit trails    │<br>│  ✓ Scalable AI architecture          │<br>└──────────────────────────────────────┘</pre><p><strong>Start with MCP</strong> for your critical data sources. Identify the 3–5 systems your AI must access — whether that’s your CRM, databases, document repositories, or external APIs — and build or use existing MCP servers for them.</p><p><strong>Develop Skills</strong> for your key workflows. Work with domain experts to document their methodologies in Skills. A good first project is often report generation or data analysis where workflows are established but time-consuming.</p><p><strong>Combine them</strong> for end-to-end automation. Once you have both data access and encoded expertise, you can build AI agents that truly understand your business.</p><p><strong>Choose Your Implementation Path:</strong></p><ul><li><strong>Use existing standards</strong>: Adopt Anthropic’s MCP and Skills implementations if they fit your needs</li><li><strong>Build custom solutions</strong>: Like Keiji AI, implement these architectural patterns in your own infrastructure optimized for your domain</li><li><strong>Hybrid approach</strong>: Use standard MCP for common integrations, custom implementations for specialized needs</li></ul><p>The power lies in the architecture, not the specific implementation. The best part? Because MCP is an open standard and the modular patterns are universal, you’re not locked into any single vendor. Build once, benefit across your entire AI stack, regardless of which LLMs or platforms you choose to use.</p><h3>The Road Ahead</h3><p>We’re in the early days, but adoption is accelerating. Thousands of MCP servers exist, and major AI companies are adopting these patterns. Industries from healthcare to finance are building their own implementations.</p><p><strong>The key insight:</strong> These aren’t proprietary features — they’re emerging as architectural standards for AI agent design. Whether you call it “MCP” or build your own protocol, standardized tool calling with secure sandboxes is becoming universal. Whether you call them “Skills” or “modules” or “guidance,” separating domain expertise from prompts is proving essential.</p><p>Companies like Keiji AI with TrialMind prove you can implement these principles in your own systems, optimized for your domain, without vendor lock-in.</p><p>The promise: AI that’s connected, knowledgeable, compliant, and actually useful for your organization’s specific work. That’s not a distant future — it’s happening now.</p><h3>Key Takeaways</h3><ul><li><strong>MCP</strong> is an open standard for standardized data connectivity — a protocol concept, not proprietary software</li><li><strong>Skills</strong> represent the pattern of modular, domain-specific expertise packages — an architectural approach applicable to any AI system</li><li><strong>Together</strong>, these concepts enable AI that’s both connected to data and knows how to use it properly</li><li><strong>Implementation flexibility</strong>: TrialMind demonstrates these principles can be implemented in custom platforms optimized for specific domains (clinical research, in their case)</li><li><strong>Core concepts are universal</strong>: Secure sandboxes + tool calling + modular knowledge = effective AI agent architecture</li><li><strong>Critical for compliance</strong>: Built-in audit trails and validated workflows make AI suitable for regulated industries</li><li><strong>The future</strong>: Not about specific vendors, but about architectural patterns for building capable, trustworthy AI agents</li></ul><p><strong>The Bottom Line:</strong> Whether you use Anthropic’s implementation, build your own like Keiji AI did, or use another provider’s tools, the architectural principles of separating data access from domain expertise are what make AI agents truly effective in production environments.</p><p><strong>Further Reading:</strong></p><ul><li>Model Context Protocol: <a href="https://modelcontextprotocol.io/">https://modelcontextprotocol.io/</a></li><li>Claude Skills Documentation: <a href="https://www.claude.com/blog/skills-explained">https://www.claude.com/blog/skills-explained</a></li><li>Anthropic Courses: <a href="https://anthropic.skilljar.com/">https://anthropic.skilljar.com/</a></li></ul><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=bd0f017b185f" width="1" height="1" alt=""><hr><p><a href="https://medium.com/keiji-ai/understanding-ais-new-power-duo-mcp-and-claude-skills-bd0f017b185f">Understanding AI’s New Power Duo: MCP and Claude Skills</a> was originally published in <a href="https://medium.com/keiji-ai">Keiji AI</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Predicting Clinical Trial Success: From Machine Learning to Agentic AI and Beyond]]></title>
            <link>https://medium.com/keiji-ai/predicting-clinical-trial-success-from-machine-learning-to-agentic-ai-and-beyond-3ab570737f83?source=rss-5c0308f333cc------2</link>
            <guid isPermaLink="false">https://medium.com/p/3ab570737f83</guid>
            <category><![CDATA[clinical-trials]]></category>
            <category><![CDATA[trial-outcome-prediction]]></category>
            <dc:creator><![CDATA[Jimeng]]></dc:creator>
            <pubDate>Thu, 13 Nov 2025 13:38:34 GMT</pubDate>
            <atom:updated>2025-11-18T04:55:28.493Z</atom:updated>
            <content:encoded><![CDATA[<p>November 5, 2025 · Zifeng Wang, PhD, Keiji AI</p><p>Predicting whether a clinical trial will succeed sounds like science fiction. Imagine knowing ahead of time whether a study will fail to reach its endpoint: like having a “what-if” medicine that lets you redo your design before the real one even begins. Tempting, right? People have been chasing this idea for years. But it’s not alchemy. It’s machine learning, finding patterns in the successes and failures of past trials to forecast the future ones.</p><h3>Defining Success: The HINT Model</h3><p>First, let’s pin down what we mean by “trial outcome.” In our first study, HINT <a href="https://keiji.ai/blog/predicting-clinical-trial-success-with-ai-from-hint-to-spot-and-beyond#ref1">[1]</a>, we defined it in a concrete way: a trial is successful if the drug it tests ultimately gains regulatory approval. That simple definition allowed us to label more than ten thousand trials, spanning phases I to III. HINT used a hierarchical model that combines drug, disease, and design features to predict whether a trial’s design has the ingredients for success.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/904/0*vcqAiykRpiibh2H2.png" /></figure><p>You can think of HINT as looking at a snapshot: given a trial, it judges whether the setup looks promising or flawed. But trials don’t exist in isolation. A trial’s fate often depends on what else is happening around it. Imagine a cancer drug aiming to cut mortality by 20%. Sounds great, until a competitor reports 40%. Suddenly your trial may be terminated early or lose regulatory traction.</p><h3>Dynamic Evolution: The SPOT Model</h3><p>That is exactly what we tackled next with SPOT <a href="https://keiji.ai/blog/predicting-clinical-trial-success-with-ai-from-hint-to-spot-and-beyond#ref2">[2]</a>. SPOT models trials not as static points, but as evolving stories. It groups similar trials into “topics”, say, all the PD-1 inhibitors for lung cancer, and learns from how those trials have evolved over time. It treats each topic as a sequence, capturing how design choices and outcomes progress from one generation to the next. Under the hood, SPOT uses sequential learning and meta-learning, letting it adapt quickly to new trial patterns even when data are sparse. The result: up to 21.5% better prediction accuracy in early-phase trials. More importantly, the model starts to reason like an experienced clinician-scientist, not just guessing, but recognizing when the “game has changed.”</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/904/0*skpUReP19ZH7_AZ9.png" /></figure><h3>Building the Foundation: CTO and TrialPanorama</h3><p>Now, algorithms are only half the story. In AI, data are often the real bottleneck. The rise of large language models has reminded everyone of a simple truth: scale and quality of data matter more than any clever model tweak. That’s why we built CTO, short for Clinical Trial Outcome labeling <a href="https://keiji.ai/blog/predicting-clinical-trial-success-with-ai-from-hint-to-spot-and-beyond#ref3">[3]</a>. CTO uses LLMs to automatically extract structured outcome labels — positive, negative, terminated, or approved, from hundreds of thousands of trial reports and publications. It’s like creating the “ImageNet” for trial outcomes, a data backbone that allows models like SPOT to train on far richer and more diverse examples.</p><p>But if outcomes are the “answers,” what about the “questions”? To make accurate predictions, models need detailed inputs about each trial, what disease, which population, what endpoints, what competing studies exist. That’s where TrialPanorama <a href="https://keiji.ai/blog/predicting-clinical-trial-success-with-ai-from-hint-to-spot-and-beyond#ref4">[4]</a> comes in. It aggregates over 1.6 million clinical trials from fifteen global registries, linking them with DrugBank, MedDRA, and PubMed. Think of it as a panoramic map of global clinical research, capturing every piece of the puzzle: designs, drugs, biomarkers, and outcomes. On top of that, it defines benchmark tasks like arm design, eligibility criteria, and trial completion prediction, helping researchers systematically test and improve AI models for trials.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/764/0*XCqaBfxOkW1T6cEd.png" /></figure><h3>The Future: Agentic AI Systems</h3><p>So, where does this all lead? We’re moving from predictive models to agentic AI systems: agents that can reason about trial outcomes the way humans do, but at machine speed and scale. Because in real life, evaluating whether a trial will “succeed” is not just about the protocol. It involves checking literature to justify the target mechanism, monitoring competing trials, benchmarking efficacy against market comparators, and even estimating the economic return if approved.</p><p>At Keiji AI, we’re building prototypes of these multi-agent systems. Imagine an AI analyst team where one agent scans new literature, another monitors live trial databases, another cross-references biomarkers with patient registries: all feeding evidence to a reasoning core that synthesizes a probability of success. It’s not magic, but it’s getting close to the scientific assistant every clinical developer wishes they had.</p><p>Predicting trial outcomes will never be perfectly deterministic: after all, biology loves to surprise us. But with data-rich foundations like CTO and TrialPanorama and adaptive models like HINT and SPOT, AI can make those surprises far less costly. We’ll share more soon about how our trial intelligence agents reason, argue, and update predictions in real time.</p><h3>References</h3><p>[1] Fu, T., Huang, K., Xiao, C., Glass, L. M., &amp; Sun, J. (2022). HINT: Hierarchical Interaction Network for Clinical Trial Outcome Prediction. <em>Patterns</em>, 3(4). <a href="https://doi.org/10.1016/j.patter.2022.100445">https://doi.org/10.1016/j.patter.2022.100445</a></p><p>[2] Wang, Z., Xiao, C., &amp; Sun, J. (2023). SPOT: Sequential Predictive Modeling of Clinical Trial Outcome with Meta-Learning. <em>ACM BCB</em>. <a href="https://dl.acm.org/doi/abs/10.1145/3584371.3613001">https://doi.org/10.1145/3584371.3613001</a></p><p>[3] Gao, C., Pradeepkumar, J., Das, T., Thati, S., &amp; Sun, J. (2024). Automatically Labeling Clinical Trial Outcomes: A Large-Scale Benchmark for Drug Development. <em>arXiv preprint arXiv:2406.10292</em>. <a href="https://arxiv.org/pdf/2406.10292">https://arxiv.org/pdf/2406.10292</a></p><p>[4] Wang, Z., et al. (2025). TrialPanorama: Database and Benchmark for Systematic Review and Design of Clinical Trials. <em>arXiv preprint arXiv:2505.16097</em>. <a href="https://arxiv.org/pdf/2505.16097">https://arxiv.org/pdf/2505.16097</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=3ab570737f83" width="1" height="1" alt=""><hr><p><a href="https://medium.com/keiji-ai/predicting-clinical-trial-success-from-machine-learning-to-agentic-ai-and-beyond-3ab570737f83">Predicting Clinical Trial Success: From Machine Learning to Agentic AI and Beyond</a> was originally published in <a href="https://medium.com/keiji-ai">Keiji AI</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Developing Generative AI for Clinical Trial Recruitment: From Patient to Trials]]></title>
            <link>https://medium.com/@jimeng_57761/developing-generative-ai-for-clinical-trial-recruitment-from-patient-to-trials-e0744f0becc3?source=rss-5c0308f333cc------2</link>
            <guid isPermaLink="false">https://medium.com/p/e0744f0becc3</guid>
            <category><![CDATA[ai-for-clinical-trials]]></category>
            <dc:creator><![CDATA[Jimeng]]></dc:creator>
            <pubDate>Wed, 05 Nov 2025 04:33:01 GMT</pubDate>
            <atom:updated>2025-11-05T04:33:47.857Z</atom:updated>
            <content:encoded><![CDATA[<p><strong>By Zifeng Wang, PhD, Keiji AI</strong></p><p>Full paper: <a href="https://www.nature.com/articles/s41467-024-53081-z">https://www.nature.com/articles/s41467-024-53081-z</a></p><p>Patient recruitment is the headache no one talks about at parties. Trials stall. Budgets burn. Great ideas never meet the right people. That is why many teams are turning to generative AI to help. In the research world, folks split the problem into two directions. Trial to patient means a trial is hunting for candidates tucked inside hospital records and registries. Patient to trial is the flip side. A clinician or a motivated patient asks which trials might fit and wants a trustworthy short list. Same mission, different starting point.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*SB4NEgodN_A2NFtuTMMK_A.png" /></figure><p>This post digs into patient to trial. Think about the inputs you see in the real world. Sometimes it is a simple question like find me an active lung cancer trial nearby. Other times it is a stack of clinic notes, pathology reports, lab panels, and a medication list that is three lines long. The job is the same. Read the record. Search the universe of trials. Decide who fits which criteria and rank the options so a human can make a call with confidence.</p><p>That is the core idea behind our research project TrialGPT. The pipeline is simple to describe and hard to execute well. Step one. Parse the patient record. Step two. Query and retrieve promising trials. Step three. Check eligibility criterion by criterion and produce a ranked list. Generative models give us a shot at doing this without the giant labeled datasets that usually power machine learning. In computer science speak, they are pretty good at zero shot learning. In human speak, you can describe the task in plain language, give a few examples, and the model gets to work.</p><p>Here is what that looks like in practice. You hand the model a patient note. You ask it to surface the nuggets that matter for matching. Age. Sex. Diagnosis and histology. Stage. Biomarkers. Lines of therapy. ECOG. Key comorbidities. Concurrent medications that might collide with an exclusion rule. It writes these down in a tidy, structured summary. Now you can talk to a trial database in its own native language. We built a tool wrapper around the public clinical trials registry so the model can compose clean search requests. The model generates search keywords that a human might forget on a busy day and plugs them into a hybrid retrieval system that mixes exact matches and semantic similarity. That gives you a shortlist of active trials, not a firehose.</p><p>Next comes the part clinicians care most about. For each candidate trial, the model walks through the inclusion and exclusion criteria one by one. It explains the reasoning in plain language. It points to the exact sentences in the patient note that support that decision. It labels the outcome for each criterion. Included. Not included. Not enough information. Not applicable. Then it aggregates those findings into a per trial score so you can sort the list and quickly spot deal breakers.</p><p>If you have ever tried to automate this, you know the hard questions show up fast. How do you know the model is making good calls. First, you measure. We worked with collaborators to build a set of patient note to criterion annotations and tested the system against those labels. We also asked medical experts to review explanations and evidence spans so we were not only checking the answer but also where the answer came from. Second, you show your work in the interface. A ranked list is helpful. A ranked list that also shows criterion level decisions and the lines from the note that drove them is something a clinician can trust and override if needed.</p><p>A big benefit of this approach is speed. Recruiters and research nurses spend a lot of time scanning criteria just to say no for a clear reason. When the system calls out which exclusion points are triggered and highlights the evidence, screening becomes a quick decision instead of a deep dive. And when the system is unsure and flags not enough information, that prompts a targeted chart check rather than a hunt through every prior visit.</p><p>Let’s bring it back to the human in the loop. No one wants a black box telling a patient yes or no. TrialGPT is built to assist, not replace. It narrows the field, surfaces reasons, and organizes evidence. A recruiter remains the decision maker. In our experience, this combination saves time on screening and increases consistency across team members. That time gets reinvested in calling the right patients and closing the loop with referring clinicians.</p><p>Where does this go next. Two directions. On the patient to trial side, the playbook is to keep expanding the inputs the model can handle and to plug into more trial registries beyond a single database so coverage improves. On the trial to patient side, which we will talk about in the next post, the problem flips. You start from a trial and translate its criteria into queries that find eligible patients across electronic health records while respecting privacy and governance. The tools are similar. The orchestration is different. Together, the two directions can make recruitment proactive rather than reactive.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=e0744f0becc3" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Powering the Next Generation of Clinical Research: How MCP Unleashes TrialMind Agents]]></title>
            <link>https://medium.com/keiji-ai/powering-the-next-generation-of-clinical-research-how-mcp-unleashes-trialmind-agents-d0c8588006c9?source=rss-5c0308f333cc------2</link>
            <guid isPermaLink="false">https://medium.com/p/d0c8588006c9</guid>
            <category><![CDATA[ai-for-clinical-trials]]></category>
            <dc:creator><![CDATA[Jimeng]]></dc:creator>
            <pubDate>Sat, 21 Jun 2025 01:41:25 GMT</pubDate>
            <atom:updated>2025-11-18T04:55:17.393Z</atom:updated>
            <content:encoded><![CDATA[<p>With pharmaceutical companies spending over $50 billion annually on clinical development while facing 90% failure rates, the strategic imperative for AI-driven innovation has never been clearer. This transformation hinges on overcoming fundamental challenges: the isolation of Large Language Models (LLMs) from real-world data, the fragmentation of data sources, and the stringent regulatory demands of the biomedical sector.</p><p>Enter the <strong>Model Context Protocol (MCP)</strong>, an open standard introduced by Anthropic in late 2024, aiming to be the “USB-C port for AI applications”. MCP standardizes how AI models securely interact with external data sources and tools, replacing bespoke, one-off integrations with a unified, scalable protocol. This architectural shift is not merely an API evolution but a paradigm shift in integration philosophy, enabling truly context-aware and actionable AI systems.</p><p>For a system like <strong>Keiji AI’s TrialMind</strong>, an advanced suite of AI agents dedicated to supporting clinical research, performing data analysis and optimizing clinical trials, MCP is not just beneficial — it’s foundational. By leveraging MCP, TrialMind agents can overcome the limitations of isolated LLMs, delivering <strong>precise, auditable, and real-time insights </strong>across the entire drug development lifecycle.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*K8vXWcbUJ5_Lz1ejWSoHAA.png" /><figcaption><strong>MCP Architecture</strong> powers standardized integration between TrialMind AI agents and diverse clinical data sources. By mediating access through a secure and auditable protocol, MCP connects LLMs like GPT and Claude to systems such as PubMed, EHRs, ClinicalTrials.gov, CDISC/OMOP databases, and genomic repositories — enabling real-time, compliant, and explainable AI-driven insights for biostatisticians, data scientists, and clinical researchers.</figcaption></figure><h3>The Technical Foundation: MCP’s Architecture for Agentic AI</h3><p>MCP operates on a client-server architecture. <strong>MCP Servers</strong> are lightweight programs that expose specific data sources or functionalities via the MCP standard, while <strong>MCP Clients</strong> (embedded within AI applications like Claude Desktop or other AI tools) connect to these servers, relaying requests and responses between the AI model and external systems. Communication between clients and servers is typically JSON-based (using JSON-RPC), making it language-agnostic.</p><p>The protocol defines core “primitives” that an AI can interact with on the server side:</p><ul><li><strong>Tools</strong>: Executable functions that allow the AI to perform actions in the external world, such as querying a database, searching the web, or manipulating files.</li><li><strong>Resources</strong>: Structured data or documents that the server can send to the AI, enriching its context.</li><li><strong>Prompts</strong>: Pre-defined instructions or templates that can guide AI interactions or formatting.</li></ul><p>This structured approach allows AI agents to dynamically discover and utilize capabilities without rigid, predefined calls, transforming traditional APIs into context-aware capabilities.</p><h3>TrialMind Agents in Action: Leveraging MCP for Clinical Trial Optimization</h3><p>Let’s explore how MCP enables specific <strong>TrialMind</strong> agent functionalities in the complex clinical trial environment:</p><h4>1. TrialMind-SLR: Literature Mining Agent for Systematic Literature Reviews</h4><p>For pharmaceutical R&amp;D and biotech research, scientists require seamless access to a multitude of information sources: scientific literature, patents, genomic datasets, and internal experimental results. A vanilla LLM is limited to its training data cutoff date, rendering it “blind” to current information.</p><p><strong>TrialMind-SLR</strong>, powered by MCP, overcomes this by integrating with specialized biomedical data sources through standardized server implementations. MCP’s flexible architecture enables seamless connectivity to authoritative research databases, providing “tools” that can:</p><ul><li><strong>Query PubMed</strong>: An MCP-enabled LLM, part of TrialMind-Lit, can invoke a literature_search tool to dynamically retrieve the latest scientific papers based on specific keywords (e.g., &quot;inhibitors of protein XYZ reported in the last 5 years&quot;). This ensures the AI&#39;s insights are always grounded in current research, moving beyond its static training data.</li><li><strong>Search ClinicalTrials.gov</strong>: The agent can utilize a trial_searcher tool to find ongoing or completed clinical trials for specific conditions or with certain genetic markers. This streamlines competitive landscape analysis and trial design.</li></ul><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*5GkT6mmDUxh44f3KpOoW7Q.png" /><figcaption><strong>TrialMind-SLR</strong> uses MCP tools to transform natural language queries into structured literature, trial, and patent searches — streamlining evidence synthesis across PubMed, ClinicalTrials.gov, and IP databases.</figcaption></figure><p><strong>Technical Insight:</strong> The elegance lies in MCP standardizing the invocation. Instead of bespoke API calls for each database, TrialMind-Lit’s LLM sends a structured MCP request to specialized data servers. These servers then handle the complexities of querying PubMed’s API or ClinicalTrials.gov’s underlying database, abstracting this detail from the AI model and presenting the results in a format the LLM can readily consume as context. This dramatically enhances productivity by eliminating manual website visits or complex query writing.</p><h3>2. TrialMind-DSA: Data Science Assistant</h3><p>Pharma organizations face persistent challenges due to fragmented clinical and real-world data across EHRs, registries, CDISC/OMOP repositories, and legacy data systems. TrialMind-Data, powered by Keiji AI’s foundation model and MCP (modular connector protocol), acts as an enterprise-grade data science assistant, enabling seamless access, analysis, and auditability across these diverse datasets.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*GWCay30-lZfnPoWoj8nc7w.png" /><figcaption><strong>TrialMind-DSA</strong> enables biostatisticians and data scientists to evaluate eligibility, run feasibility analyses, and generate synthetic models across EHR, OMOP, and registry data — with full audit trails and GxP-ready outputs via MCP.</figcaption></figure><p><strong>Eligibility Criteria Evaluation</strong><br> TrialMind-Data can dynamically evaluate protocol criteria against real-world EHR or claims datasets by querying CDISC/OMOP-compliant databases. For example, a user might ask, “How many patients in our EHR meet the exclusion criteria for Trial XYZ?” TrialMind-Data can retrieve the matched cohort, estimate recruitment rates, and generate visualizations — all without writing code.</p><p><strong>Real-Time Feasibility Analysis</strong><br> Instead of relying on static Excel templates, teams can use TrialMind-Data to ask in natural language: “What are the time-to-treatment distributions for 2L NSCLC patients in our dataset?” The agent interfaces with structured databases and statistical libraries to return plots, summary statistics, and reusable R or Python code for further validation.</p><p><strong>Synthetic Data Validation and Modeling</strong><br> With access to synthetic patient data generated by TrialMind’s digital twin module, TrialMind-Data can simulate rare population cohorts, run stratified analyses, or test ML-based outcome prediction models. This is especially useful for exploring protocol modifications or augmenting small datasets during study planning phases.</p><p><strong>Technical Insight</strong><br> Every interaction through TrialMind-Data is logged through the MCP architecture — recording access history, parameter settings, and analytical output — enabling full audit trails required for GxP compliance. For example, if a regulatory reviewer questions the basis for eligibility rates used in trial design, the system can trace back to the original query, source dataset, and code used, ensuring transparency and reproducibility.</p><h3>3. TrialMind-Optimize: AI Agents for Trial Design, Recruitment, and Outcome Prediction</h3><p>Modern clinical development is overwhelmed by data complexity and cross-functional dependencies. TrialMind-Optimize, powered by Keiji AI’s suite of specialized AI models and the MCP (Modular Connector Protocol), provides intelligent agents that support protocol optimization, patient recruitment, and trial outcome forecasting — enabling smarter, faster clinical trials.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*gVXYX9YTtlIYyLR2x3CUfw.png" /><figcaption><strong>TrialMind-Optimize</strong> connects AI models through the MCP Hub to deliver secure, auditable optimization of protocol design, patient recruitment, risk prediction, and regulatory documents.</figcaption></figure><p><strong>Trial Design &amp; Eligibility Optimization</strong><br> TrialMind-Optimize includes <em>AutoTrial</em>, a specialized model that generates inclusion/exclusion criteria aligned with target indication, endpoint, and protocol objectives. By analyzing 400K+ historical clinical trials and incorporating user prompts, the model produces customized eligibility drafts that improve both regulatory alignment and recruitment feasibility. Through MCP, it can retrieve protocol precedents from internal repositories for comparative analysis.</p><p><strong>Patient Recruitment &amp; Trial Matching</strong><br> Leveraging <em>TrialGPT</em>, TrialMind-Optimize uses natural language to identify suitable patients from EHR systems integrated via FHIR-based MCP servers. The model ranks and explains trial matches better than clinicians, achieving &gt;90% recall and 87% explanation accuracy. When integrated with site data, it automatically filters patients based on trial criteria and prioritizes those most likely to enroll.</p><p><strong>Trial Outcome Prediction &amp; Simulation</strong><br> TrialMind’s <em>SPOT</em> model (Sequential Predictive Modeling of Trial Outcomes) forecasts trial results based on baseline characteristics, previous trial data, and simulated patient cohorts. This capability allows teams to assess risk, refine endpoints, or redesign arms — especially useful in oncology or rare disease trials. Combined with synthetic patient data generated by TrialMind’s <em>Digital Twin</em> module, users can simulate counterfactuals to test design decisions before costly execution.</p><p><strong>Ongoing Monitoring &amp; Quality Assurance (QA)</strong><br> TrialMind-Optimize connects to EDC systems via MCP to track trial progress in real-time. It flags anomalies such as protocol deviations, overdue labs, or serious adverse events. Because every interaction is logged with precise version control, TrialMind ensures full GxP-compliant audit trails — supporting regulatory inspections and internal QA.</p><p><strong>Regulatory Document Assembly</strong><br> When generating submission-ready content — such as efficacy summaries, informed consent forms, or SAP appendices — TrialMind-Optimize pulls from validated sources using versioned MCP calls. Models like <em>InformGen</em> assist in drafting site-customized, regulation-compliant documents with alignment to FDA guidelines.</p><p><strong>Technical Insight</strong><br> MCP’s modularity and traceability enable scalable, enterprise-ready deployment of AI agents. Each connector acts as a secure, auditable interface to internal systems — whether clinical data warehouses, document repositories, or trial protocol archives. TrialMind’s models can reuse these interfaces across functions, speeding up AI integration and reducing compliance burden. For proprietary systems, Claude 4, or similar LLMs can even co-develop new MCP servers, accelerating integration cycles.</p><h3>The Future of Clinical Trials: A Unified AI Ecosystem</h3><p>MCP, and its application in agent suites like <strong>Keiji AI’s TrialMind</strong>, signifies a profound shift in how AI systems will integrate into clinical trials. By providing a common “language” and framework for AI-data interactions, MCP allows for:</p><ul><li><strong>Enhanced Interoperability</strong>: AI models can dynamically integrate with diverse systems (EHRs, LIMS, databases, web services) from various vendors, fostering a rich, connected ecosystem.</li><li><strong>Robust Security &amp; Compliance</strong>: MCP’s built-in features for secure connections, granular permissions, standardized authentication, and comprehensive logging transform AI from a “black box” into a transparent, governable system. This is paramount for meeting FDA/EMA expectations for AI transparency, reproducibility, and data privacy. While MCP does introduce new security considerations like prompt injection or token theft, its standardized nature also means that robust security standards and advanced monitoring can be built specifically for MCP implementations.</li><li><strong>Reproducibility and Auditability</strong>: The ability to capture the entire context of an AI operation — including tool calls, data retrieved, and versions — is a game-changer for scientific rigor and regulatory accountability.</li><li><strong>Reduction of Hallucinations</strong>: By enabling real-time queries to authoritative sources, MCP grounds AI responses in factual data, significantly reducing the likelihood of generating incorrect or outdated information.</li><li><strong>Scalability for Agentic AI</strong>: MCP facilitates complex, multi-step agent workflows where different AI agents or tools can collaborate, orchestrating sequences of actions across disparate systems.</li></ul><p>With TrialMind, a <strong>clinical scientist</strong> can simply ask, “What’s the expected enrollment rate for this protocol in the U.S.?” and receive a fully sourced, reproducible answer — grounded in real-world data, past trial designs, and predictive models. A <strong>biostatistician</strong> can validate interim results by querying SDTM/ADaM datasets and comparing them against SAP-defined endpoints — without writing a single line of code. A <strong>clinical data scientist</strong> can simulate alternative eligibility criteria, assess recruitment impact, and re-run time-to-event models — all with full traceability, code reuse, and statistical rigor.</p><p>Every action is explainable, every dataset is permissioned, and every result is regulatory-ready. <strong>This is not just the future of AI in clinical trials — it’s what TrialMind delivers today. </strong>TrialMind is your AI-native teammate for faster, smarter, and safer clinical development.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=d0c8588006c9" width="1" height="1" alt=""><hr><p><a href="https://medium.com/keiji-ai/powering-the-next-generation-of-clinical-research-how-mcp-unleashes-trialmind-agents-d0c8588006c9">Powering the Next Generation of Clinical Research: How MCP Unleashes TrialMind Agents</a> was originally published in <a href="https://medium.com/keiji-ai">Keiji AI</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Being a Computer Science Professor: The Ultimate Career in the Age of AI]]></title>
            <link>https://medium.com/@jimeng_57761/being-a-computer-science-professor-the-ultimate-career-in-the-age-of-ai-70d510c5d67c?source=rss-5c0308f333cc------2</link>
            <guid isPermaLink="false">https://medium.com/p/70d510c5d67c</guid>
            <dc:creator><![CDATA[Jimeng]]></dc:creator>
            <pubDate>Sat, 17 May 2025 13:56:35 GMT</pubDate>
            <atom:updated>2025-05-17T13:56:35.584Z</atom:updated>
            <content:encoded><![CDATA[<p>In the fast-paced world of technology, where industry giants offer eye-popping salaries and glamorous perks, choosing academia might seem counterintuitive. Yet, as someone who made the leap from industry research to academia over a decade ago, I can confidently say that becoming a Computer Science professor has been the most rewarding decision of my professional life. Let me share why this path represents the pinnacle of intellectual fulfillment, even — perhaps especially — in today’s AI-driven landscape.</p><h3>The Unexpected Joys of Academic Dedication</h3><p>Recently, I faced a choice that perfectly encapsulates the academic experience: attend my PhD students’ hooding ceremony or make an important trip to San Francisco. The trip required an overnight stay at Chicago O’Hare and catching the first morning flight. When faced with this scheduling conflict, there was no question in my mind — I would be there for my students’ milestone achievement.</p><p>As it turned out, the hotel was oversold, leaving me without a room at 1 AM. The next morning, my flight was delayed, forcing me to cancel the San Francisco trip entirely. When one of my graduating students thanked me for attending their ceremony, they seemed surprised by my presence. To me, it wasn’t even a question — witnessing their achievement of the highest educational degree was as much my triumph as theirs.</p><p>This moment crystallized why being a CS professor at institutions like Georgia Tech and now UIUC has been such a privilege. Even with the exciting opportunities in industry AI research, I remain convinced that academia offers something uniquely fulfilling.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*BRW0mRevlIpiMVgL" /></figure><h3>The Unmatched Benefits of Academic Life</h3><h3>Perpetual Learning in a Field Transforming the World</h3><p>As a CS professor, you’re learning every day. The rapidly evolving field of computer science, especially AI, creates an exhilarating environment where new papers, demos, and breakthroughs constantly emerge. You feel intimately connected to movements that are reshaping society. Modern AI tools have made this learning process even more accessible and efficient.</p><p>This constant intellectual growth keeps you mentally young and engaged. Unlike many careers where expertise plateaus, computer science academia demands continuous evolution. Each semester brings fresh challenges, new research directions, and opportunities to expand your knowledge horizon.</p><h3>Cross-Disciplinary Collaboration with Brilliant Minds</h3><p>CS and AI have become foundational to virtually every discipline, creating unprecedented opportunities for cross-pollination of ideas. As a CS professor specializing in AI, I’ve had the privilege of collaborating with outstanding researchers from healthcare, medicine, and pharmaceuticals. These partnerships have led to research that wouldn’t have been possible within the confines of a single department or company.</p><p>These collaborations aren’t just professionally rewarding — they’re intellectually invigorating. When you bridge disciplines, you see your own field through new lenses and discover applications you might never have considered otherwise.</p><h3>Unparalleled Intellectual Freedom</h3><p>While industry positions typically offer substantially higher compensation, they rarely match the intellectual freedom of academia. As a CS professor, you function as the CEO of your own research lab. Beyond teaching responsibilities and some service commitments, you possess remarkable latitude to pursue topics that genuinely excite you — at least within the American university system.</p><p>Yes, the funding landscape can be competitive and occasionally heartbreaking. But even with these constraints, CS professorship offers intellectual autonomy that’s virtually unmatched in any other setting. Industry researchers often face pressure to align their work with product timelines and business objectives; as a professor, your primary allegiance is to knowledge advancement.</p><h3>Unmatched Opportunities for Real-World Translation</h3><p>One of the most exciting aspects of being a CS professor is the ability to translate research directly into real-world impact through entrepreneurship. Universities have dramatically evolved their approach to commercialization, creating robust ecosystems that support faculty startups. As a CS professor, you can readily launch companies — often with your own students — to bring your innovations to market.</p><p>Most top universities now provide comprehensive support mechanisms including seed grants, accelerator programs, patent assistance, and specialized legal guidance. These institutions have recognized that commercialization creates a virtuous cycle: successful startups generate resources that flow back to research, attract talented students, and enhance the university’s reputation.</p><p>The professor-entrepreneur path is particularly powerful in computer science, where the gap between research prototype and viable product has narrowed considerably. A machine learning algorithm developed in your lab on Monday could become a startup’s core technology by Friday. This opportunity to see your ideas transform industries while training the next generation of entrepreneurial technologists represents a uniquely satisfying career dimension that purely academic or purely industrial positions cannot match.</p><h3>The Joy of Mentoring Brilliant Young Minds</h3><p>Perhaps the most profound joy of academic life is being surrounded by exceptionally bright, motivated students. Many professors describe their graduate students as the intellectual children they’re privileged to mentor: smart, disciplined, curious, and determined to push research boundaries.</p><p>Participating in their journey is both exciting and deeply fulfilling. Their energy and fresh perspectives keep you mentally agile and connected to emerging ideas. Despite any age gap, the collaborative nature of academic research creates a unique relationship — part mentor, part colleague — that bridges generations.</p><p>I’ve witnessed senior colleagues who remain at the cutting edge of research decades into their careers, often because their work with graduate students keeps them intellectually youthful and engaged with new paradigms.</p><h3>The Hidden Benefits Industry Can’t Match</h3><p>Beyond these primary advantages, academia offers several less obvious but equally significant benefits:</p><p><strong>Legacy and Influence</strong>: Through your students, your intellectual impact multiplies exponentially. As they advance to positions in industry, academia, and government, your ideas and approaches ripple outward in ways impossible to achieve alone.</p><p><strong>Teaching as Learning</strong>: Explaining complex concepts to bright undergraduate and graduate students forces you to develop deeper understanding. The questions they ask often illuminate aspects of problems you hadn’t fully considered.</p><p><strong>Schedule Flexibility</strong>: While academic life is demanding, it offers unparalleled flexibility. You can structure much of your work around your most productive hours and personal commitments.</p><p><strong>Global Community</strong>: Academia connects you to an international network of scholars. Conference travel, sabbaticals, and visiting appointments enrich both your research and personal experiences.</p><p><strong>Meaningful Impact</strong>: Your research and teaching can influence both fundamental knowledge and practical applications, allowing for contributions with both intellectual depth and real-world significance.</p><h3>The Counter-Arguments and Reality Check</h3><p>Of course, academia isn’t without challenges. Industry salaries for AI and CS specialists have skyrocketed, creating a widening compensation gap. The tenure process can be stressful, and securing research funding requires persistent effort. Teaching loads vary significantly between institutions, and administrative duties can consume valuable time.</p><p>Yet for those drawn to intellectual exploration, these challenges are counterbalanced by benefits no industry position can match. Many accomplished professors maintain industry connections through consulting, startups, or sabbaticals, creating hybrid careers that combine academic freedom with industry engagement.</p><h3>Conclusion: A Moment That Captures Everything</h3><p>At a recent hooding ceremony, I watched as over 360 PhD graduates walked the stage in a procession that stretched across two full hours. Among them was my student, who later confided something profound: “While waiting for the walk, it seemed to take forever, but when it actually happened to me, it was so fast.”</p><p>Those words resonated deeply because they perfectly capture the essence of the academic journey in computer science. Viewed from the outside, the progress of academia — the years of research, the incremental discoveries, the patient mentoring — might appear glacially slow compared to the breakneck pace of industry. But when you’re immersed in the revolution, participating in those breakthroughs firsthand, experiencing those moments of discovery alongside brilliant young minds — it all happens with exhilarating speed.</p><p>When I watched my students cross that stage, families beaming with pride all around us, something stirred inside me that no salary increase or stock option could ever match. At that moment, I saw not just their achievement but a living continuation of ideas that began in late-night discussions on Zoom, and in collaborative breakthroughs that kept us working past midnight. I saw the future of our field taking human form.</p><p>These are the moments that remind me why I chose this path. Being a CS professor isn’t just about research papers and lectures — it’s about becoming part of something larger than yourself. It’s about nurturing sparks of brilliance and watching them ignite into flames that will illuminate corners of computing I could never reach alone. It’s about creating a legacy that lives not in products that will be obsolete in five years, but in minds that will create and discover for decades.</p><p>The CS academic journey is fast-paced and exciting in ways that transcend traditional metrics of career progression. From the outside, earning tenure or building a lab might seem like a marathon. But when you’re in the midst of it — celebrating a student’s first publication, watching your research become a startup, seeing your graduates go on to change the world — you realize these moments flash by with breathtaking speed.</p><p>The industry offers many rewards, and I respect those who choose that path. But for those who feel called to the unique blend of mentorship, discovery, and creation that defines the academic life, remember this: enjoy every moment and make a difference! The professor’s chair isn’t just another seat at the table — it’s a front-row view to computing’s future, with the rare privilege of helping shape who and what that future will become.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=70d510c5d67c" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Clinical Trials Demystified: An AI Researcher’s Guide (Part 2)]]></title>
            <link>https://medium.com/keiji-ai/clinical-trials-demystified-an-ai-researchers-guide-part-2-8ebf78214394?source=rss-5c0308f333cc------2</link>
            <guid isPermaLink="false">https://medium.com/p/8ebf78214394</guid>
            <category><![CDATA[ai-for-clinical-trials]]></category>
            <category><![CDATA[ai]]></category>
            <category><![CDATA[clinical-trials]]></category>
            <dc:creator><![CDATA[Jimeng]]></dc:creator>
            <pubDate>Wed, 12 Mar 2025 03:09:04 GMT</pubDate>
            <atom:updated>2025-11-18T04:54:56.665Z</atom:updated>
            <content:encoded><![CDATA[<h3>Clinical Trials Demystified: An AI Researcher’s Guide (Part 2) — Clinical Trial Software &amp; Vendors</h3><p>Jimeng Sun (Keiji AI)</p><p>Clinical development is supported by a suite of specialized software systems collectively referred to as “eClinical” tools. These systems manage data capture, documentation, operational logistics, and patient engagement.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*sd5DqDnVzmNzLdEZ" /><figcaption>Overview of Clinical Trial Software</figcaption></figure><h3>Electronic Data Capture (EDC)</h3><p>EDC systems are used to collect and manage clinical trial data electronically, replacing paper case report forms. They provide a web-based interface for site staff to enter data, with built-in validation checks, query management, and audit trails to ensure data quality and regulatory compliance (e.g. 21 CFR Part 11 for electronic records (<a href="https://www.sofpromed.com/what-is-an-electronic-data-capture-edc-system-in-clinical-trials#:~:text=The%20regulatory%20requirements%20that%20EDC,21%20CFR%20Part%2011">What is an Electronic Data Capture (EDC) System in Clinical Trials? — Sofpromed</a>). Major EDC vendors in the industry include <strong>Medidata Rave EDC</strong>, <strong>Oracle InForm</strong>, and <strong>Anju TrialMaster</strong>, which are among the most widely used platforms globally. These enterprise EDC solutions offer advanced features: for example, automated edit checks, medical coding tools (to code adverse events via dictionaries like MedDRA), and integration with other systems (like lab data imports). <br><strong>Pros</strong>: EDC greatly improves data accuracy and speeds up data cleaning and analysis. Data can be reviewed in real-time, and remote monitoring is enabled. <br><strong>Cons</strong>: Clinical trials commonly experience delays linked to extended clinical data management cycle times. On average, building and releasing a study database takes about 68 days, while data entry occurs roughly 8 days after each patient visit. Additionally, there is an average lag of 36 days from the final patient visit to the database lock. Notably, sponsors typically encounter longer cycle times compared to CROs, requiring around 73 days versus 53 days for database setup, and 39 days compared to 28 days to finalize database locking. These differences suggest areas where sponsors can optimize processes to reduce clinical trial delays. Commercial EDCs can be costly and require training for site users. <br><strong>Technical specifics</strong>: modern EDCs are cloud-hosted and often support CDISC CDASH standards for data fields to facilitate downstream integration. There are also <strong>open-source EDC</strong> options (e.g. OpenClinica, REDCap) primarily used in academic trials, which are lower cost but may have fewer features (<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3049639/#:~:text=like%20DADOS%20prospective%2C%20OpenClinica%20and,more%20common%20in%20academic%20settings"> Electronic Data Capture for Registries and Clinical Trials in Orthopaedic Surgery: Open Source versus Commercial Systems — PMC</a> ). Regardless of vendor, using an EDC is now considered industry-standard for trial data management, as it ensures that the trial’s data is attributable, legible, contemporaneous, original, and accurate (the ALCOA principles).</p><h3>Electronic Trial Master File (eTMF)</h3><p>The Trial Master File is the collection of all essential documents for a trial (protocol, investigator brochures, IRB approvals, patient consent forms, monitoring reports, etc.). An <strong>eTMF system</strong> is a specialized content management system for organizing these documents in electronic form, maintaining version control and audit trails, and ensuring “inspection readiness.” It essentially serves as a digital archive of all trial documentation required by GCP (ICH E6) (<a href="https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf#:~:text=1,Documents%20for%20the%20Conduct%20of">GUIDELINE FOR GOOD CLINICAL PRACTICE</a>). Leading eTMF vendors include <strong>Veeva Vault eTMF</strong> (a market leader noted for its comprehensive functionality and potentially high cost (<a href="https://www.reddit.com/r/clinicalresearch/comments/1c8iiw8/edc_etmf/#:~:text=EDC%2C%20eTMF%20%3A%20r%2Fclinicalresearch%20,Cheap%20eTMF%E2%80%94%20which%20isn%27t">EDC, eTMF : r/clinicalresearch — Reddit</a>), <strong>TransPerfect Trial Interactive</strong>, <strong>Phlexglobal’s PhlexTMF</strong>, <strong>Aurea Clinical Compliance Manager</strong>, and Medidata (offers an eTMF solution integrated with Rave) (<a href="https://www.withpower.com/guides/top-solutions-for-e-tmf-clinical-trials#:~:text=Medidata%20Rave%20eTMF">Top Solutions for eTMF Clinical Trials | Power</a>). For example, <strong>Veeva Vault eTMF</strong> provides real-time tracking of document status, remote access for study stakeholders, and automated naming/indexing conventions, helping sponsors maintain control over TMF completeness. <strong>Trial Interactive</strong> (by TransPerfect) emphasizes ease of use and integration with other eClinical systems.</p><p><strong>Pros</strong>: eTMFs significantly streamline document management — no shipping paper binders, easier search and retrieval, and simultaneous access for multiple parties (sponsor, CRO, site) with appropriate permissions. They also facilitate compliance by prompting users for missing documents and enabling auditors to review files remotely.</p><p><strong>Cons</strong>: Implementation requires migration of existing documents and training. Inconsistent use by staff can lead to gaps (e.g. if documents aren’t uploaded timely).</p><p><strong>Technical specifics</strong>: Most eTMFs are cloud-based web applications with strict security controls, electronic signature support, and metadata tagging based on a standard structure (often following the DIA TMF Reference Model). The <strong>top eTMF systems by market share</strong> have been reported as Veeva (leading in 2018) (<a href="https://www.marketsandmarkets.com/Market-Reports/electronic-trial-master-file-system-market-94357456.html#:~:text=Electronic%20Trial%20Master%20File%20Systems,be%20attributed%20to%20its">Electronic Trial Master File Systems Market — Global Forecast to 2024</a>), with others like Phlexglobal, TransPerfect, and <strong>Oracle</strong> (which has an eTMF module) also recognized as key players (<a href="https://reports.valuates.com/market-reports/QYRE-Othe-2D460/global-electronic-trial-master-file-etmf-systems#:~:text=Size%20reports,Phlexglobal%20Limited%2C%20TransPerfect%20Global%2C">Electronic Trial Master File (eTMF) Systems Market Size</a>).</p><h3>Clinical Trial Management System (CTMS)</h3><p>A CTMS is a project management and operational system for clinical trials. It helps sponsors and contract research organizations (CROs) plan and track various trial activities — site initiation status, enrollment numbers, visit scheduling, case report form completion, monitoring visits, site payments, etc. Essentially, CTMS provides a centralized dashboard of trial progress and automates many trial oversight tasks. Leading CTMS solutions include <strong>Oracle Siebel CTMS</strong> (a long-standing system widely used by big pharma and CROs), <strong>Medidata</strong> (offers CTMS as part of their Clinical Cloud, building on their acquisition of CTMS technology), <strong>Veeva Vault CTMS</strong> (cloud-based and often adopted alongside Veeva eTMF for an integrated suite) (<a href="https://infiuss.com/insights/next-generation-ctms-platforms-for-clinical-trials#:~:text=Health%20infiuss,Oracle">Next-Generation CTMS Platforms for Clinical Trials — Infiuss Health</a>). Some CTMS cater to site networks or smaller sponsors, for example <strong>Bio-Optronics Clinical Conductor CTMS</strong> (now part of Advarra) is popular among research sites, and <strong>Advarra OnCore</strong> is widely used in academic medical centers for managing their trial portfolios (<a href="https://www.advarra.com/about-advarra/news/advarra-and-huron-join-forces-to-optimize-clinical-research-site-performance/#:~:text=to%20benefit%20our%20clients%20and,%E2%80%9D">Advarra and Huron Join Forces to Optimize Clinical Research Site Performance — Advarra</a>). <strong>Pros</strong>: CTMS centralizes operational data — allowing project managers to see which sites are lagging in enrollment, which monitoring reports are due, and to generate status reports. Integration of CTMS with EDC can auto-populate enrollment metrics and visit data, reducing duplicate data entry (<a href="https://evidentiq.com/library/clinical-trial-software/#:~:text=What%20are%20the%20main%20clinical,seamless%20data%20exchange%20and">What are the main clinical software? EDC, RTSM, CTMS, eTMF …</a>). CTMS also often handles investigator payments and tracking of regulatory documents expiry (like IRB approvals) for each site. <br><strong>Cons</strong>: Historically, some CTMS implementations have been seen as cumbersome or underutilized if not well integrated into workflows. They can involve significant configuration to fit an organization’s processes. Modern CTMS are improving usability and moving to cloud/SaaS models. <strong>Technical specifics</strong>: Many CTMS now offer APIs to connect with EDC and eTMF systems, enabling an <strong>“eClinical ecosystem”</strong> where data flows between systems. For instance, a protocol amendment document in eTMF could trigger updates to relevant fields in CTMS; or an enrollment entered in EDC updates the recruitment dashboard in CTMS (<a href="https://evidentiq.com/library/clinical-trial-software/#:~:text=What%20are%20the%20main%20clinical,seamless%20data%20exchange%20and">What are the main clinical software? EDC, RTSM, CTMS, eTMF …</a>). According to industry reports, top CTMS vendors for pharma in 2024 include Medidata, Oracle, Veeva, Clario (through the merger of ERT &amp; Bioclinica), MasterControl, and IBM (<a href="https://pharmainsider.medium.com/top-8-clinical-trial-management-systems-ctms-in-2024-7cc28f3c60e5#:~:text=2024%20pharmainsider,IBM%20Clinical%20Development">Top 8 Clinical Trial Management Systems (CTMS) in 2024</a>), reflecting a mix of specialized clinical tech firms and broader enterprise software firms.</p><h3>Randomization and Trial Supply Management (RTSM)</h3><p>RTSM systems provide automated, web-based platforms crucial for participant randomization and trial supply chain management in clinical research. These systems offer sophisticated randomization methods, such as stratified and adaptive techniques, ensuring balanced and unbiased participant allocation. RTSM solutions streamline inventory management by offering real-time stock visibility, proactive forecasting, and automated alerts to prevent supply chain disruptions. Integration capabilities with complementary systems such as Electronic Data Capture (EDC), electronic Trial Master Files (eTMF), and Clinical Trial Management Systems (CTMS) ensure seamless data exchange and operational efficiency.</p><p>Top providers of RTSM solutions include Medidata (Rave RTSM, integrated with Rave EDC), Oracle (Clinical One RTSM, part of Oracle’s Clinical One suite), Almac (IXRS 3), Veeva RTSM (integrated with Veeva Vault platform), and Suvoda (specialized in complex and adaptive randomization).</p><p><strong>Pros</strong>: RTSM solutions significantly reduce selection bias and enhance trial integrity through advanced randomization algorithms. Real-time inventory management features, such as proactive forecasting and automated alerts, prevent supply disruptions. Integration capabilities with other clinical software ensure efficient data flow and trial management. User-friendly interfaces and robust scalability further contribute to operational efficiency.<br><strong>Cons</strong>: Implementation of RTSM systems may require significant training and setup time, especially for complex platforms. Costs can be high, particularly for fully integrated solutions like Medidata and Oracle. User interfaces may vary in intuitiveness, leading to potential adoption challenges. Integration outside a vendor’s ecosystem might also present difficulties.<br><strong>Technical specifics</strong>: RTSM solutions typically operate as cloud-hosted, web-based SaaS platforms. They offer robust randomization capabilities, including adaptive and stratified algorithms. Systems comply with regulatory standards such as 21 CFR Part 11, GDPR, and various ISO standards. Comprehensive REST API integrations allow for seamless connectivity with other clinical trial systems, supporting scalability for global, multicenter clinical trials.</p><h3>Real-World Data (RWD) Analytics Platforms</h3><p>Beyond data collected directly in the trial, researchers increasingly leverage real-world data sources (e.g. electronic health records, insurance claims, patient registries, genomic databases) to inform trial design and supplement evidence. RWD analytics platforms provide tools to query and analyze such data for clinical research purposes. One important use is in <strong>feasibility analysis</strong> — determining how many potential trial-eligible patients exist in a network and where, to guide site selection and enrollment targets. Leading platforms include <strong>TriNetX</strong> and <strong>IQVIA’s E360</strong>, which aggregate de-identified patient data from many healthcare organizations. TriNetX, for example, offers access to a “living ecosystem” of global clinical data on millions of patients and analytics to explore protocol criteria against that data (<a href="https://trinetx.com/#:~:text=Welcome%20to%20the%20world%E2%80%99s%20largest%2C,life%20sciences%20and%20healthcare%20communities">Real-world data for the life sciences and healthcare | TriNetX</a>). Using TriNetX, a sponsor can input proposed eligibility criteria and query how many patients meet them, and at which hospitals — crucial for planning realistic trials. Another key player is <strong>Aetion</strong>, whose Evidence Platform is used for generating regulatory-grade real-world evidence; notably, the FDA has partnered with Aetion to analyze observational data (such as for COVID-19 treatments) using its validated analytics software (<a href="https://news.aetion.com/fda-aetion-rwe-advance-regulatory-science-innovation#:~:text=science%20and%20innovation,This%20project%20is">FDA selects Aetion Evidence Platform | Aetion FDA Regulatory Science</a>). Other vendors include <strong>Flatiron Health</strong> (focused on oncology EHR data), <strong>HealthVerity</strong> and <strong>Verana Health</strong> for specialty registries, and <strong>SAS</strong> as an analytics tool often used for RWD statistical analysis.</p><p><strong>Pros</strong>: RWD analytics can dramatically speed up trial planning and even provide external control data (reducing the need for large placebo groups in some trials). They can also help in post-market studies and pharmacovigilance by providing a larger context for trial findings. <br><strong>Cons</strong>: Real-world datasets are often noisy, heterogeneous, and may contain biases; effective utilization requires careful data curation and sometimes advanced methods to address confounding factors. Additionally, cohort queries can be challenging for medical users and trial designers, as natural language queries for accessing real-world data are still in development. Data privacy remains a paramount concern—these platforms operate on de-identified or aggregated data to protect patient identities. There is hope that AI advancements will enhance the querying process and improve usability in this area.<br><strong>Technical specifics</strong>: Platforms like TriNetX operate as a federated network where hospital data stays within the institution’s firewall but is query-able in aggregate, often using a cloud-based user interface (<a href="https://trinetx.com/#:~:text=Leverage%20global%20real,evidence%20generation%2C%20and%20drug%20safety">TriNetX: Real-world data for the life sciences and healthcare</a>). Advanced analytics (including AI) are employed to map different coding systems and normalize data (e.g., mapping ICD diagnoses and lab units across sources). The output of RWD queries can inform protocol design or serve as supplementary evidence alongside trial data.</p><h3>Electronic Clinical Outcome Assessment (eCOA)</h3><p>eCOA systems enable the electronic collection of clinical outcome data, which can include patient-reported outcomes (ePRO), clinician-reported outcomes (ClinRO), observer-reported outcomes, and performance outcomes. Commonly, this refers to <strong>ePRO</strong> — patients using a tablet, smartphone app, or web interface to report symptoms, diary entries, or quality-of-life questionnaires. eCOA replaces paper questionnaires with electronic formats, ensuring time stamps and data integrity. Top providers of eCOA solutions include <strong>Signant Health (SmartSignals eCOA)</strong>, <strong>Clario eCOA</strong> (from the ERT/Bioclinica merger, historically ERT was a leader in ePRO for cardiac and respiratory trials), <strong>Medidata eCOA</strong> (part of Medidata’s unified platform, integrates with Rave EDC), <strong>Suvoda</strong>, <strong>IQVIA eCOA</strong>, <strong>Castor ePRO</strong>, <strong>YPrime</strong>, and <strong>WCG eCOA</strong> — among others (<a href="https://www.withpower.com/guides/top-providers-of-e-pro-and-e-coa-in-clinical-trials#:~:text=Top%20Providers%20of%20ePRO%20and,%C2%B7%20YPrime%20%C2%B7%20WCG%20eCOA%2FePRO">Top Providers of ePRO and eCOA in Clinical Trials | Power</a>). These systems often provide provisioned devices (tablets or smartphones) to patients or allow “bring your own device” (BYOD) approaches via secure apps. Features typically include configurable questionnaires with logic checks, reminders/alerts to patients for scheduled assessments, and real-time data transmission to the study database.</p><p><strong>Pros</strong>: eCOA improves data quality and patient compliance — entries are time-stamped (no back-dating), and patients cannot accidentally skip questions due to forced entry fields. Data from ePRO devices flows in more rapidly for review, and there is evidence that patients prefer electronic entry over cumbersome paper diaries. Moreover, eCOA can include multimedia capabilities (for example, patients can be shown a video on how to perform an assessment, or can upload a photo of an injection site reaction if the protocol calls for it). <br><strong>Cons</strong>: It requires that patients (or site staff for ClinRO) are trained on the devices/apps. There can be technical issues — lost devices, software glitches, or compliance issues if patients are not tech-savvy. Provisioning devices adds cost and logistical complexity (shipping devices, providing support). Data privacy and security are critical, especially if devices are collecting data in real time. <br><strong>Technical specifics</strong>: eCOA systems must comply with 21 CFR Part 11 as well (for electronic records) and often go through extensive validation. Many vendors boast a library of pre-validated PRO instruments (questionnaires) in multiple languages, which can be quickly deployed. Integration is also key: modern eCOA solutions can feed data into the EDC or data warehouse so that patient-reported outcomes sit alongside clinical data. Some eCOA providers (e.g. Signant, IQVIA) also bundle related services like eConsent and randomization (IRT), offering a unified platform.</p><h3>Institutional Review Board (IRB) Management Systems</h3><p>These systems (also called eIRB systems) are used by ethics committees or IRBs to manage the submission, review, and tracking of clinical trial protocols and related documents for ethics approval. While not always directly used by sponsors, they are crucial at the site/institution level for compliance. Many academic medical centers use platforms like <strong>IRBNet</strong> (a widely adopted web-based IRB management tool) or <strong>Huron Research Suite (Click IRB)</strong>, and independent IRBs have their own portals (for example, <strong>Advarra CIRBI</strong> is Advarra IRB’s electronic system, and <strong>WCG IRB Connexus</strong> for WCG IRB). These systems allow investigators to submit new protocols, amendments, continuing reviews, and report adverse events to the IRB electronically. They track approvals, send reminders for upcoming renewal deadlines, and document IRB decisions and rosters. For institutions running many studies, an IRB system provides an organized workflow and central document repository, often integrated with institutional training records (ensuring researchers have completed ethics training).</p><p><strong>Pros</strong>: eIRB systems improve transparency and efficiency in the ethics review process — researchers can see the status of their submission, IRB members can comment and request revisions in a central place, and approval letters are stored and easily accessible. They also enforce completeness (not allowing submission unless all required fields/documents are provided) and can ensure regulatory checklists are completed for each review. <br><strong>Cons</strong>: From the researcher side, some systems can be perceived as user-unfriendly or bureaucratic if too many forms or logins are required. There’s also fragmentation: a sponsor dealing with many sites might interact with multiple different IRB portals used by each institution, which is inefficient (this is being addressed partly by centralized IRBs). <br><strong>Technical specifics</strong>: IRB management systems focus heavily on compliance — for instance, they log every action to an audit trail and comply with 21 CFR Part 11 for e-signatures on approvals (<a href="https://www.advarra.com/blog/choosing-your-electronic-irb-system-a-guide-for-sites/#:~:text=,automatic%20routing%20to%20the%20radiation">Choosing Your Electronic IRB System: A Guide for Sites — Advarra</a>). Many have customizable workflows to accommodate each IRB’s processes and checklists (<a href="https://www.advarra.com/blog/choosing-your-electronic-irb-system-a-guide-for-sites/#:~:text=protocol%20and%20IRB%20policies,workflows%20include%20automation%20to%20help">Choosing Your Electronic IRB System: A Guide for Sites — Advarra</a>). Modern eIRB solutions increasingly seek to integrate with CTMS or site management systems. Notably, Advarra (a major IRB services company) and Huron’s eIRB platform are the major players (<a href="https://www.advarra.com/about-advarra/news/advarra-and-huron-join-forces-to-optimize-clinical-research-site-performance/#:~:text=to%20benefit%20our%20clients%20and,%E2%80%9D">Advarra and Huron Join Forces to Optimize Clinical Research Site Performance — Advarra</a>). In summary, while IRB systems might not be as famous by name in the wider industry, they are a critical piece of software at the research site level to ensure <strong>ethical compliance</strong> and documentation of informed consent processes.</p><h3>Patient Recruitment &amp; Engagement Platforms</h3><p>Enrolling patients is often one of the biggest bottlenecks in trials, and a variety of software solutions exist to assist in finding, engaging, and retaining patients. <strong>Patient recruitment platforms</strong> typically leverage databases of patients or online outreach to identify potential participants. For example, <strong>Antidote</strong> and <strong>TrialScope</strong> curate trial listings (often from ClinicalTrials.gov) and match interested patients to trials using eligibility criteria algorithms. <strong>AutoCruitment</strong> uses digital advertising across 1500+ channels to find and pre-screen patients online (<a href="https://guides.clarahealth.com/best-clinical-trial-recruitment-companies/#:~:text=22%20Best%20Clinical%20Trial%20Companies,randomize%20patients%20for%20clinical%20trials">22 Best Clinical Trial Companies For Patient Recruitment In 2023</a>). <strong>Trialbee</strong> provides a software platform for tracking referrals and enrollment funnel metrics. Many of these companies offer services as well as technology — e.g., running social media campaigns, handling prescreening calls via call centers, etc., and then use a CRM-like software to manage the leads. Additionally, some site networks (like <strong>Elligo Health Research</strong>) use their EHR integrations to find patients in real time and contact their physicians. On the <strong>patient engagement</strong> side, once patients are enrolled, retention can be improved with tools like <strong>patient portals</strong> or apps that remind patients of visits, provide study information, and even offer travel or stipend management. For instance, <strong>Greenphire ClinCard</strong> and <strong>Clincierge</strong> (now part of Greenphire) focus on patient convenience by handling reimbursement and travel logistics, which indirectly encourages enrollment and retention. There are also wearables and telemedicine platforms that became especially important for <strong>decentralized trials</strong> — e.g., apps for eConsent and televisits, which keep patients engaged from home.</p><p><strong>Pros</strong>: Recruitment platforms can dramatically widen outreach — instead of relying solely on physician referrals, trials can reach patients directly through online tools. This can be crucial for rare diseases or trials needing diverse populations. Indeed, AI-driven recruitment tools can help improve diversity by identifying sites or regions with higher concentrations of minority populations and targeting those areas (<a href="https://drug-dev.com/clinical-trials-the-power-of-ai-in-overcoming-patient-diversity-challenges/#:~:text=To%20remove%20discriminatory%20biases%2C%20AI,using%20a%20mix%20of">The Power of AI in Overcoming Patient Diversity Challenges</a>). Engagement tools, meanwhile, reduce drop-out rates by keeping patients informed and satisfied (for example, sending medication reminders or providing a direct line to ask questions). <strong>Cons</strong>: One challenge is <strong>lead quality</strong> — digital campaigns can generate many inquiries, but a small percentage might actually be eligible and enroll, so without careful management this could waste effort. AI can potentially help improve the lead quality(<a href="https://www.nature.com/articles/s41467-024-53081-z">Matching patients to clinical trials with large language models</a>). Data privacy is another concern: recruitment often involves handling health information from potential participants, so platforms must ensure consent and compliance with regulations (HIPAA in the US, GDPR in Europe, etc.). Over-reliance on online recruitment might also skew demographics (e.g., underrepresenting those without internet savvy or access). <br><strong>Technical specifics</strong>: Many recruitment platforms use predictive analytics and natural language processing. For example, NLP can parse free-text criteria and patient health data to find matches. Some use social media data and search data to target advertising to likely candidates (raising ethical questions about privacy). Integration is also a theme — e.g., integrating referral management with the site’s CTMS to know when a referred patient actually randomizes. Notably, a number of specialized <strong>patient recruitment companies</strong> offer both tech and service; a 2025 ranking of top firms included names like <em>Patiro, Antidote, AutoCruitment, CitrusLabs, Clinical Trial Media, Continuum Clinical, CSSi, and Elligo</em> among others (<a href="https://www.patiro.com/insights/top-20-best-clinical-trial-recruitment-companies-2025#:~:text=Patiro%20www,Elligo%20Health%20Research">Top 20 Best Clinical Trial Recruitment Companies 2025 — Patiro</a>). Sponsors often partner with such vendors to accelerate enrollment, and their platforms provide real-time analytics on recruitment status across sites.</p><p><strong>In summary</strong>, the clinical trial software landscape is broad and often interconnected. Vendors are increasingly providing <strong>integrated platforms</strong> that combine several of the above functionalities to simplify the user experience. For instance, some EDC vendors also offer randomization and trial supply management (RTSM), some CTMS vendors bundle eTMF, etc. When evaluating these tools, sponsors and sites consider factors like feature set, ease of use, integration capability, regulatory compliance, and cost. Each category plays a role in making trials more efficient: EDC and eCOA improve data quality, CTMS and eTMF improve oversight and compliance, and patient-centered tools improve recruitment and data collection — and many leverage AI/automation under the hood (like automatic query generation in EDC or AI-assisted document indexing in eTMF (<a href="https://www.clinicalleader.com/doc/phlexglobal-announces-industry-first-etmf-ai-0001#:~:text=Phlexglobal%20Announces%20Industry,improving%20TMF%20quality%2C%20completeness%2C">Phlexglobal Announces Industry-First eTMF AI That Reduces Risk …</a>). The overarching goal, supported by these technologies, is to conduct trials faster, more cheaply, and with high quality data, while adhering to the complex regulatory requirements of GCP.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=8ebf78214394" width="1" height="1" alt=""><hr><p><a href="https://medium.com/keiji-ai/clinical-trials-demystified-an-ai-researchers-guide-part-2-8ebf78214394">Clinical Trials Demystified: An AI Researcher’s Guide (Part 2)</a> was originally published in <a href="https://medium.com/keiji-ai">Keiji AI</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
    </channel>
</rss>